



CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome: FEDERICI MASSIMO

Nazionalità: Italiana

Iscritto all'Albo dei Medici Chirurghi e Odontoiatri n. 46220 - Roma

**POSIZIONE ATTUALE: PROFESSORE ORDINARIO DI MEDICINA INTERNA,
UNIVERSITÀ DI ROMA TOR VERGATA**

ESPERIENZE LAVORATIVE

• dal 1/4/2018: Direttore, Unità Operativa Complessa Medicina Interna 3, Università di Roma Tor Vergata - Policlinico Tor Vergata Nome e indirizzo del datore di lavoro: Fondazione Policlinico Tor Vergata, Via Oxford 81 00136 Roma, Italia Tipo di attività o settore: Sanità Occupazione o posizione ricoperta: Direttore UOC Medicina Interna 3, Direttore Divisione di Medicina Interna Principali attività e responsabilità: Responsabile di 22 posti letto di degenza ordinaria, 3 posti letto di Day Hospital, centro ambulatoriale (Centro per l'Aterosclerosi dedicato alla medicina geriatrica, vascolare e metabolica)

• 2018-oggi: Professore Ordinario di Medicina Interna (SSD MED/09), Università di Roma Tor Vergata

• 2011-2014: Professore di Nutrizione (SSD MED/09), Università di Roma Tor Vergata • 2011-2014: Adjunct Professor of Medicine, Department of Medicine, Division of Diabetes, University of Texas Health Science Center at San Antonio, USA • 2007-2011: Professore Ordinario di Medicina (SSD M-EDF/01), Università di Roma Tor Vergata • 2002-2006: Professore Associato di Medicina Interna (SSD MED/09), Università di Roma Tor Vergata

• 1999-2001: Ricercatore Universitario Confermato di Medicina Interna (SSD MED/09), Università di Roma Tor Vergata

ISTRUZIONE E FORMAZIONE

• 1996-1997: Research Fellowship Nome e tipo di istituto di istruzione o formazione: Joslin Diabetes Center, Harvard University, Boston, MA Principali materie / abilità professionali oggetto dello studio: Studi sulla resistenza all'insulina nel tessuto adiposo

• 1995-1999: Specializzazione in Endocrinologia e Malattie Metaboliche Nome e tipo di istituto di istruzione o formazione: Università degli Studi di Roma Tor Vergata, Roma, Italia. Endocrinologia Clinica e Sperimentale e disordini metabolici

text

Copy

1998: Tenente Medico dell'Aeronautica Militare Italiana

• 1995: Iscrizione all'Albo dei Medici Chirurghi • 1988-1994: Laurea in Medicina e Chirurgia Nome e tipo di istituto di istruzione o formazione: Università degli Studi di Roma Tor Vergata,

Formazione continua

MADRE LINGUA: ITALIANO ALTRE LINGUE: INGLESE

PRINCIPALI INCARICHI E RESPONSABILITÀ

- Da gennaio 2023: Prorettore alla Ricerca, Università degli Studi di Tor Vergata, Roma, Italia
- da gennaio 2022: Membro del Comitato Esecutivo della Fondazione Università di Tor Vergata
- 2021-2023: Co-Presidente Task Force ESC per le Linee Guida 2023 CVD/Diabete
- da novembre 2021: Direttore del Dipartimento di Medicina dei Sistemi
- 2016-2018: Componente del Comitato di Valutazione Nazionale per l'abilitazione alle funzioni di Professore di I e II fascia (ASN) per il settore 06/D2 Endocrinologia, Nefrologia e Scienze dell'Alimentazione
- 2016-2017: Membro del Gruppo di Esperti Valutatori (GEV) Area 06 – ANVUR (VQR) 2011-2014
- 2015: 51st EASD Meeting Program Committee member
- 2016-2018: Componente del Comitato di Valutazione Nazionale per l'abilitazione alle funzioni di Professore di I e II fascia (ASN) per il settore 06/D2 Endocrinologia, Nefrologia e Scienze dell'Alimentazione
- 2017-2019: Vice-Presidente della Facoltà di Medicina e Chirurgia, Università di Roma Tor Vergata, Roma, Italia
- 2016-2018: Componente del Comitato di Valutazione Nazionale per l'abilitazione alle funzioni di Professore di I e II fascia (ASN) per il settore 06/D2 Endocrinologia, Nefrologia e Scienze dell'Alimentazione
- 2016-2017: Membro del Gruppo di Esperti Valutatori (GEV) Area 06 – ANVUR (VQR) 2011-2014
- 2015: 51st EASD Meeting Program Committee member
- dal 2014 ad oggi: Coordinatore del Dottorato di Ricerca in Medicina dei Sistemi e Medicina Sperimentale
- dal 2004 ad oggi: Attività tutoriale post-laurea presso l'Università di Roma Tor Vergata (dottorato di ricerca, specializzazione in endocrinologia, geriatria, medicina interna)

COMPETENZE ORGANIZZATIVE

Buone capacità e competenze organizzative acquisite durante la direzione di: Dipartimento di Medicina dei Sistemi di UTOV, Coordinamento del Dottorato di Ricerca in Medicina dei Sistemi e Medicina Sperimentale, Direzione del Centro Ambulatoriale dedicato al Rischio Cardiovascolare (>10000 visite/anno), coordinamento di progetti di ricerca presso il Laboratorio di Medicina Molecolare dell'Università di Tor Vergata (>7Milion€) 2002-2024

GRANT AUDITOR • 2017-2019: Program Manager, Cardiovascular Funding Program, EFSD 2017-2019 • Call 2017: British Heart Foundation • Calls 2012-2016: Juvenile Diabetes Research Foundation Research • Call 2013: European Foundation for the Study of Diabetes • 2012: NIH DP3 grant applications • 2010-2012: French National Research Agency (ANR), member of the Evaluation Committee SVSE1 • Call NMP.2011.1.2: European Commission FP7 • Call 2009: Netherlands Organisation for Scientific Research (NWO) • Call 2008: Fondazione Ricerca Società Italiana di Diabetologia • Call 2008: European Foundation for the Study of Diabetes

PRINCIPALI ESPERIENZE DI RICERCA (PROGETTI FINANZIATI NEGLI ULTIMI 10 ANNI)

- 2023-2026 PNRR MAD-2022-12376543 ATHEROMICS, national PI
- 2022-2026 PNC DARE Spoke 3 National PI "Secondary and tertiary Digital Prevention"
- 2022-2026 PNRR Heal Italia Spoke 1 WP3 Leader Microbial Metabolites and Diabetes
- 2022-2024 EFSD/Sanofi European Research Programme "3-HIB"
- 2020-2025 SOPHIA "Stratification of Obese Phenotypes to Optimize Future Obesity Therapy", H2020 Innovative Medicine Initiative 2
- 2020-2022 PON ARS01_00876 BIO-D (Principal Investigator)
- 2019-2021 National Coordinator, PRIN Project prot. 2017FM74HK "MICROBESOMICS: effect of gut microbiome on "obesitytypes" in human subjects"
- 2016-2019 Co-PI, PRIN Project prot. 2015MPESJS_004 "Molecular, translational and clinical aspects of age-related metabolic diseases"
- 2015-2018 Co-PI Italian Ministry of Health project RF-2011-02349921 "The role of the brain-adipocyte axis activity in potentiating antidepressant efficacy"
- 2014-2016 National Coordinator, PRIN Project prot. 20123BJ89E "Genes, environment and metabolism: predictors, modifiers and markers of vascular aging and cardiometabolic risk"
- 2014-2017 Juvenile Diabetes Research Foundation grant 2014-262 "Modulation of TIMP3/ADAM17 dyad to block Diabetic Nephropathy" (Principal Investigator)
- 2013-2016 EFSD/LILLY European Research Programme "TIMP3 modulates immune cell microenvironment in a model of metabolic disease" (Principal Investigator)
- 2012-2014 AIRC IG 13163 "Exploring TIMP3 as potential therapeutic agent in obesity-related hepatocellular carcinoma" (Principal Investigator)
- 2011-2013 PRIN/MIUR 2009FATVW3_002 "The role of cluster Mir-216/Mir-217 in metabolic disease" (Principal Investigator)
- 2008-2012 Juvenile Diabetes Research Foundation grant 1-2007-665 "Role of Regulated Membrane Proteolysis in diabetes vascular complications" (Principal Investigator)
- 2008-2011 TELETHON GRANT GGP08065 "Testing Timp3 as a switch to block metabolic and vascular complications of obesity" (Principal Investigator)

PREMI E RICONOSCIMENTI

- 2018 Italian Society of Endocrinology Career Prize
- 2012 Alcmeone Career Prize, Italian Society of Diabetes

- 2005 Award Italian Society of Endocrinology (under 40 years old)
- 2005 EASD Rising Star Lecture
- 2005 Morgagni Silver Award, University of Padua
- 2001 Award Italian Society of Endocrinology (under 35 years old)
- 1997 Award Italian Society of Endocrinology (under 30 years old)

EDITORIAL BOARDS

- 2018-to date Editorial Board, Atherosclerosis
- 2012-2013 Editorial Board, Diabetes Care
- 2009-2017 Associate Editor, Atherosclerosis
- 2009-2013 Academic Editor, PlosOne
- 2022-to date Editor in chief, Acta Diabetologica
- 2007-to date Guest Editor, Cell Death and Differentiation
- 2007-2017 Editorial Board, Cell Death and Disease

PREMI E RICONOSCIMENTI

- 2018: Premio alla Carriera della Società Italiana di Endocrinologia
- 2012: Premio Alcmeone alla Carriera, Società Italiana di Diabetologia
- 2005: Premio della Società Italiana di Endocrinologia (under 40 years old)
- 2005: EASD Rising Star Lecture • 2005: Premio Morgagni Silver, Università di Padova
- 2001: Premio della Società Italiana di Endocrinologia (under 35 years old)
- 1997: Premio della Società Italiana di Endocrinologia (under 30 years old)

COMITATI EDITORIALI

- 2018-ad oggi: Editorial Board, Atherosclerosis
- 2012-2013: Editorial Board, Diabetes Care
- 2009-2017: Associate Editor, Atherosclerosis

- 2009-2013: Academic Editor, PlosOne
- 2022-to date: Editor in chief, Acta Diabetologica
- 2007-to date: Guest Editor, Cell Death and Differentiation
- 2007-2017: Editorial Board, Cell Death and Disease

RUOLI DA ADVISOR

- : • 2007 LILIANE BETTENCOURT PRIZE FOR LIFE SCIENCES

CONSULENTE PER PROFESSORSHIP SELECTION: • Harvard University, Leeds University

REVISORE PER:

Circulation, JACC, Cell Death and Differentiation, Lancet Gastroenterology, Diabetes, Diabetes Care, ATVB, JCEM, JBC, Stem Cells, Am J Cardiology, Cytokine, Cardiovascular Diabetology, NMCD, Diab Vasc Dis Res, Cell Death and Disease, Journal of Biological Chemistry, Atherosclerosis, Endocrinology, Nature Medicine, Gut Microbes, Nature Medicine, GUT

COLLABORAZIONI INTERNAZIONALI

Role of Gut Microbiome in NCDs and Aging Prof. Remy Burcelin, INSERM Toulouse, France Prof. Josè Manuel Fernandez Real, University of Girona, Spain Prof. Marc E. Dumas, Imperial College London, UK

Role of Circadian Rhythms in NCDs and Aging Prof. Bart Staels, INSERM Lille, France Prof. Nikolaus Marx, University of Aachen, Germany

BIBLIOMETRIC DATA (SOURCE: SCOPUS 2025)

- H-index: 70 • No. pubblicazioni: 305 • No. citazioni: 23000

PUBBLICAZIONI (selezione)

1. Sesti G, D'Alfonso R, Vargas Punti MD, Tullio AN, Liu YY, Federici M, Borboni P, Marini MA, Lauro R, Fusco A. Delayed intracellular dissociation of the insulin-receptor complex impairs receptor recycling and insulin processing in cultured Epstein-Barr virus-transformed lymphocytes from insulin-resistant subjects. *Diabetologia*. 1996 Mar;39(3):289-95.
2. Valensise H, Liu YY, Federici M, Lauro D, Dell'anna D, Romanini C, Sesti G. Increased expression of low-affinity insulin receptor isoform and insulin/insulin-like growth factor-I hybrid receptors in term placenta from insulin-resistant women with gestational hypertension. *Diabetologia*. 1996 Aug;39(8):952-60.
3. Federici M, Zucaro L, Porzio O, Massoud R, Borboni P, Lauro D, Sesti G. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects. *J Clin Invest*. 1996 Dec 15;98(12):2887-93.
4. Federici M, Porzio O, Zucaro L, Fusco A, Borboni P, Lauro D, Sesti G. Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues. *Mol Cell Endocrinol*. 1997 May 16;129(2):121-6.
5. Federici M, Porzio O, Zucaro L, Giovannone B, Borboni P, Marini MA, Lauro D, Sesti G. Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. *Mol Cell Endocrinol*. 1997 Nov 30;135(1):41-7.
6. Federici M, Lauro D, D'Adamo M, Giovannone B, Porzio O, Mellozzi M, Tamburrano G, Sbraccia P, Sesti G. Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia. *Diabetes*. 1998 Jan;47(1):87-92.

7. Federici M, Porzio O, Lauro D, Borboni P, Giovannone B, Zucaro L, Hribal ML, Sesti G. Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity. *J Clin Endocrinol Metab.* 1998 Aug;83(8):2911-5.
8. Porzio O, Marlier LN, Federici M, Hribal ML, Magnaterra R, Lauro D, Fusco A, Sesti G, Borboni P. GLUT2 and glucokinase expression is coordinately regulated by sulfonylurea. *Mol Cell Endocrinol.* 1999 Jul 20;153(1-2):155-61.
9. Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, Borboni P, Sesti G. The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. *J Clin Invest.* 1999 Aug;104(3):357-64.
10. Borboni P, Porzio O, Pierucci D, Cicconi S, Magnaterra R, Federici M, Sesti G, Lauro D, D'Agata V, Cavallaro S, Marlier LN. Molecular and functional characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic beta-cells and effects of PACAP-38 on components of the insulin secretory system. *Endocrinology.* 1999 Dec;140(12):5530-7.
11. Federici M, Giaccari A, Hribal ML, Giovannone B, Lauro D, Morviducci L, Pastore L, Tamburrano G, Lauro R, Sesti G. Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly. *Diabetes.* 1999 Dec;48(12):2277-85.
12. Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili D, Lauro R, Sesti G. The Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. *J Clin Endocrinol Metab.* 2000 May;85(5):2004-13.
13. Giovannone B, Scadaferri ML, Federici M, Porzio O, Lauro D, Fusco A, Sbraccia P, Borboni P, Lauro R, Sesti G. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. *Diabetes Metab Res Rev.* 2000 Nov-Dec;16(6):434-41.
14. Federici M, Hribal ML, Ranalli M, Marselli L, Porzio O, Lauro D, Borboni P, Lauro R, Marchetti P, Melino G, Sesti G. The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. *FASEB J.* 2001 Jan;15(1):22-24.
15. Hribal ML, D'Alfonso R, Giovannone B, Lauro D, Liu YY, Borboni P, Federici M, Lauro R, Sesti G. The sulfonylurea glimepiride regulates intracellular routing of the insulin-receptor complexes through their interaction with specific protein kinase C isoforms. *Mol Pharmacol.* 2001 Feb;59(2):322-30.
16. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, Folli F. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. *Diabetes.* 2001 Jun;50(6):1290-301.
17. Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. *Diabetes Metab Res Rev.* 2001 Sep-Oct;17(5):363-73.
18. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. *FASEB J.* 2001 Oct;15(12):2099-111.
19. Pierucci D, Cicconi S, Bonini P, Ferrelli F, Pastore D, Matteucci C, Marselli L, Marchetti P, Ris F, Halban P, Oberholzer J, Federici M, Cozzolino F, Lauro R, Borboni P, Marlier LN. NGF-withdrawal induces apoptosis in pancreatic beta cells in vitro. *Diabetologia.* 2001 Oct;44(10):1281-95.
20. Marchetti P, Lupi R, Federici M, Marselli L, Masini M, Boggi U, Del Guerra S, Patanè G, Piro S, Anello M, Bergamini E, Purrello F, Lauro R, Mosca F, Sesti G, Del Prato S. Insulin secretory function is impaired in isolated human islets carrying the Gly(972)-->Arg IRS-1 polymorphism. *Diabetes.* 2002 May;51(5):1419-24.
21. Nisticò L, Giorgi G, Giordano M, Galgani A, Petrone A, D'Alfonso S, Federici M, Di Mario U, Pozzilli P, Buzzetti R, Cascino I. IL12B polymorphism and type 1 diabetes in the Italian population: a case-control study. *Diabetes.* 2002 May;51(5):1649-50.
22. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. *Circulation.* 2002 Jul 23;106(4):466-72.
23. Sbraccia P, D'Adamo M, Leonetti F, Buongiorno A, Silecchia G, Basso MS, Tamburrano G, Lauro D, Federici M, Di Daniele N, Lauro R. Relationship between plasma free fatty acids and uncoupling protein-3 gene expression in skeletal muscle of obese subjects: in vitro evidence of a causal link. *Clin Endocrinol (Oxf).* 2002 Aug;57(2):199-207.
24. Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D'Apice MR, Massart C, Capon F, Sbraccia P, Federici M, Lauro R, Tudisco C, Pallotta R, Scarano G, Dallapiccola B, Merlini L, Bonne G. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. *Am J Hum Genet.* 2002 Aug;71(2):426-31.
25. Bernassola F, Federici M, Corazzari M, Terrinoni A, Hribal ML, De Laurenzi V, Ranalli M, Massa O, Sesti G, McLean WH, Citro G, Barbetti F, Melino G. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient. *FASEB J.* 2002 Sep;16(11):1371-8.

26. D'Alfonso R, Marini MA, Frittitta L, Sorge R, Frontoni S, Porzio O, Mariani LM, Lauro D, Gambardella S, Trischitta V, Federici M, Lauro R, Sesti G. Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2003 Jan;88(1):317-22.
27. Federici M, Petrone A, Porzio O, Bizzarri C, Lauro D, D'Alfonso R, Patera I, Cappa M, Nisticò L, Baroni M, Sesti G, di Mario U, Lauro R, Buzzetti R. The Gly972-->Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. *Diabetes.* 2003 Mar;52(3):887-90.
28. Sesti G, Cardellini M, Marini MA, Frontoni S, D'Adamo M, Del Guerra S, Lauro D, De Nicolais P, Sbraccia P, Del Prato S, Gambardella S, Federici M, Marchetti P, Lauro R. A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. *Diabetes.* 2003 May;52(5):1280-3.
29. Marini MA, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P, Baroni A, D'Alfonso R, Perna M, Lauro D, Federici M, Gambardella S, Lauro R, Sesti G.
The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. *J Clin Endocrinol Metab.* 2003 Jul;88(7):3368-71.
30. Serra C, Federici M, Buongiorno A, Senni MI, Morelli S, Segretella E, Pascuccio M, Tiveron C, Mattei E, Tatangelo L, Lauro R, Molinaro M, Giaccari A, Bouché M.
Transgenic mice with dominant negative PKC-theta in skeletal muscle: a new model of insulin resistance and obesity. *J Cell Physiol.* 2003 Jul;196(1):89-97.
31. Hribal ML, Perego L, Lovari S, Andreozzi F, Menghini R, Perego C, Finzi G, Usellini L, Placidi C, Capella C, Guzzi V, Lauro D, Bertuzzi F, Davalli A, Pozza G, Pontiroli A, Federici M, Lauro R, Brunetti A, Folli F, Sesti G. Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans. *FASEB J.* 2003 Jul;17(10):1340-2.
32. Mango R, Clementi F, Borgiani P, Forleo GB, Federici M, Contino G, Giardina E, Garza L, Fahdi IE, Lauro R, Mehta JL, Novelli G, Romeo F.
Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. *J Med Genet.* 2003 Dec;40(12):933-6.
33. Federici M, Pandolfi A, De Filippis EA, Pellegrini G, Menghini R, Lauro D, Cardellini M, Romano M, Sesti G, Lauro R, Consoli A. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. *Circulation.* 2004 Jan 27;109(3):399-405.
34. D'Alessandris C, Andreozzi F, Federici M, Cardellini M, Brunetti A, Ranalli M, Del Guerra S, Lauro D, Del Prato S, Marchetti P, Lauro R, Sesti G. Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells. *FASEB J.* 2004 Jun;18(9):959-61.
35. Andreozzi F, D'Alessandris C, Federici M, Laratta E, Del Guerra S, Del Prato S, Marchetti P, Lauro R, Perticone F, Sesti G. Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells. *Endocrinology.* 2004 Jun;145(6):2845-57.
36. Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, Perticone F, Lauro R. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. *Diabetes Care.* 2004 Jun;27(6):1394-8.
37. Perticone F, Sciacqua A, Scozzafava A, Ventura G, Laratta E, Pujia A, Federici M, Lauro R, Sesti G. Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. *J Clin Endocrinol Metab.* 2004 Jul;89(7):3606-9.
38. D'Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, Andreozzi F, Sciacqua A, Lauro D, Sbraccia P, Federici M, Paganelli M, Pontiroli AE, Lauro R, Perticone F, Folli F, Sesti G. The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes. *Diabetes.* 2004 Jul;53(7):1905-10.
39. Federici M. The strange case of G972R IRS-1 variant and diabetes. Do type 1 and type 2 diabetes share common genes? *Mol Genet Metab.* 2004 Apr;81(4):261-2.
40. Sesti G, Sciacqua A, Cardellini M, Marini MA, Maio R, Vatrano M, Succurro E, Lauro R, Federici M, Perticone F. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. *Diabetes Care.* 2005 Jan;28(1):120-5.
41. Menghini R, Marchetti V, Cardellini M, Hribal ML, Mauriello A, Lauro D, Sbraccia P, Lauro R, Federici M. Phosphorylation of GATA2 by Akt increases adipose tissue differentiation and reduces adipose tissue-related inflammation: a novel pathway linking obesity to atherosclerosis. *Circulation.* 2005 Apr 19;111(15):1946-53.
42. Federici M, Lauro R. Review article: diabetes and atherosclerosis--running on a common road. *Aliment Pharmacol Ther.* 2005 Nov;22 Suppl 2:11-5.

43. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, Sunnarborg SW, Rizza S, Serino M, Cunsolo V, Lauro D, Mauriello A, Smookler DS, Sbraccia P, Sesti G, Lee DC, Khokha R, Accili D, Lauro R. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. *J Clin Invest*. 2005 Dec;115(12):3494-505.
44. Rizza S, Tesauro M, Cardellini M, Menghini R, Bellia A, Marini MA, Lauro D, Sbraccia P, Sesti G, Lauro R, Federici M. Insulin resistance and increased intimal medial thickness in glucose tolerant offspring of type 2 diabetic subjects carrying the D298D genotype of endothelial nitric oxide synthase. *Arterioscler Thromb Vasc Biol*. 2006 Feb;26(2):431-2.
45. Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D, Fukamizu A, Lauro R, Federici M. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. *Diabetes*. 2006 Aug;55(8):2231-7.
46. Cardellini M, Marini MA, Frontoni S, Hribal ML, Andreozzi F, Perticone F, Federici M, Lauro D, Sesti G. Carotid artery intima-media thickness is associated with insulin-mediated glucose disposal in nondiabetic normotensive offspring of type 2 diabetic patients. *Am J Physiol Endocrinol Metab*. 2007 Jan;292(1):E347-52.
47. Tesauro M, Rizza S, Iantorno M, Campia U, Cardillo C, Lauro D, Leo R, Turriziani M, Cocciolillo GC, Fusco A, Panza JA, Scuteri A, Federici M, Lauro R, Quon MJ. Vascular, metabolic, and inflammatory abnormalities in normoglycemic offspring of patients with type 2 diabetes mellitus. *Metabolism*. 2007 Mar;56(3):413-9.
48. Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, Lauro D, Sbraccia P, Hribal ML, Lauro R, Federici M. Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. *Diabetes*. 2007 Oct;56(10):2541-6.
49. Porzio O, Massa O, Cunsolo V, Colombo C, Malaponti M, Bertuzzi F, Hansen T, Johansen A, Pedersen O, Meschi F, Terrinoni A, Melino G, Federici M, Decarlo N, Menicagli M, Campani D, Marchetti P, Ferdaoussi M, Froguel P, Federici G, Vaxillaire M, Barbetti F. Missense mutations in the TGM2 gene encoding transglutaminase 2 are found in patients with early-onset type 2 diabetes. Mutation in brief no. 982. *Online. Hum Mutat*. 2007 Nov;28(11):1150.
50. Fiorito M, Torrente I, De Cosmo S, Guida V, Colosimo A, Prudente S, Flex E, Menghini R, Miccoli R, Penno G, Pellegrini F, Tassi V, Federici M, Trischitta V, Dallapiccola B. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome. *Obesity (Silver Spring)*. 2007 Dec;15(12):2889-95.
51. Consoli C, Martelli E, D'Adamo M, Menghini R, Arcelli D, Porzio O, Pandolfi A, Pistolese GR, Consoli A, Lauro R, Ippoliti A, Federici M. Insulin resistance affects gene expression in endothelium. *Arterioscler Thromb Vasc Biol*. 2008 Feb;28(2):e7-9.
52. Scuteri A, Tesauro M, Rizza S, Iantorno M, Federici M, Lauro D, Campia U, Turriziani M, Fusco A, Cocciolillo G, Lauro R. Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome. *Nutr Metab Cardiovasc Dis*. 2008 Jun;18(5):349-56.
53. Hribal ML, Tornei F, Pujol A, Menghini R, Barcaroli D, Lauro D, Amoruso R, Lauro R, Bosch F, Sesti G, Federici M. Transgenic mice overexpressing human G972R IRS-1 show impaired insulin action and insulin secretion. *J Cell Mol Med*. 2008 Oct;12(5B):2096-106.
54. Rizza S, Clementi F, Porzio O, Cardellini M, Savo A, Serino M, Chiricolo G, Romeo F, Lauro R, Federici M. Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD. *Nutr Metab Cardiovasc Dis*. 2009 Jan;19(1):54-60.
55. Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, Marzano V, Tornei F, Bertucci P, Iacobini C, Serino M, Porzio O, Hribal ML, Folli F, Khokha R, Urbani A, Lauro R, Pugliese G, Federici M. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. *Gastroenterology*. 2009 Feb;136(2):663-72.
56. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, Taurino M, Serino M, Marano G, Federici M, Prizzi F, Pugliese G. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. *Arterioscler Thromb Vasc Biol*. 2009 Jun;29(6):831-6.
57. Bellia A, Giardina E, Lauro D, Tesauro M, Di Fede G, Cusumano G, Federici M, Rini GB, Novelli G, Lauro R, Sbraccia P. "The Linosa Study": epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. *Nutr Metab Cardiovasc Dis*. 2009 Sep;19(7):455-61.
58. Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, Wewer JJ, Coletta DK, Jenkinson C, Jhingan RM, Smokler D, Reyna S, Musi N, Khokha R, Federici M, Tripathy D, DeFronzo RA, Folli F. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. *Diabetologia*. 2009 Oct;52(10):2169-81.

59. Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, Porzio O, Mauriello A, Solini A, Ippoliti A, Lauro R, Folli F, Federici M. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. *Diabetes*. 2009 Oct;58(10):2396-401.
60. Rizza S, Tesauro M, Cardillo C, Galli A, Iantorno M, Gigli F, Sbraccia P, Federici M, Quon MJ, Lauro D. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. *Atherosclerosis*. 2009 Oct;206(2):569-74.
61. Menghini R, Casagrande V, Cardellini M, Martelli E, Terrinoni A, Amati F, Vasa-Nicotera M, Ippoliti A, Novelli G, Melino G, Lauro R, Federici M. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. *Circulation*. 2009 Oct 13;120(15):1524-32.
62. Rogliani P, Curradi G, Mura M, Lauro D, Federici M, Galli A, Saltini C, Cazzola M. Metabolic syndrome and risk of pulmonary involvement. *Resp Med*. 2010 Jan;104(1):47-51.
63. Fiorentino L, Vivanti A, Cavallera M, Marzano V, Ronci M, Fabrizi M, Menini S, Pugliese G, Menghini R, Khokha R, Lauro R, Urbani A, Federici M. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. *Hepatology*. 2010 Jan;51(1):103-10.
64. Rizza S, Gigli F, Galli A, Miccheli B, Lauro D, Lauro R, Federici M. Adiponectin isoforms in elderly patients with or without coronary artery disease. *J Am Geriatr Soc*. 2010 Apr;58(4):702-6.
65. Fadini GP, Albiero M, Boscaro E, Menegazzo L, Cabrelle A, Piliago T, Federici M, Agostini C, Avogaro A. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. *Cell Biol Int*. 2010 Jul;34(7):709-15.
66. Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, Federici M, Sibilia M, Blobel CP, Khokha R. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. *J Clin Invest*. 2010 Aug;120(8):2731-44.
67. Rizza S, Cardellini M, Martelli E, Porzio O, Pecchioli C, Nicolucci A, Marx N, Lauro D, Ippoliti A, Romeo F, Lauro R, Federici M. Occult impaired glucose regulation in patients with atherosclerosis is associated to the number of affected vascular districts and inflammation. *Atherosclerosis*. 2010 Sep;212(1):316-20.
68. Guglielmi V, D'Adamo M, D'Apice MR, Bellia A, Lauro D, Federici M, Lauro R, Novelli G, Sbraccia P. Elbow deformities in a patient with mandibuloacral dysplasia type A. *Am J Med Genet A*. 2010 Nov;152A(11):2711-3.
69. Federici M, Menghini R. sPLA2: linking atherosclerosis to aneurysm progression. *Atherosclerosis*. 2011 Jan;214(1):41-2.
70. Mammi C, Pastore D, Lombardo MF, Ferrelli F, Caprio M, Consoli C, Tesauro M, Gatta L, Fini M, Federici M, Sbraccia P, Donadel G, Bellia A, Rosano GM, Fabbri A, Lauro D. Sildenafil reduces insulin-resistance in human endothelial cells. *PLoS One*. 2011 Jan 28;6(1):e14542.
71. Bacci S, Rizza S, Prudente S, Spoto B, Powers C, Facciorusso A, Pacilli A, Lauro D, Testa A, Zhang YY, Di Stolfo G, Mallamaci F, Tripepi G, Xu R, Mangiacotti D, Aucella F, Lauro R, Gervino EV, Hauser TH, Copetti M, De Cosmo S, Pellegrini F, Zoccali C, Federici M, Doria A, Trischitta V. The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. *Diabetes*. 2011 Mar;60(3):1000-7.
72. Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, Senese N, Lauro D, Sbraccia P, Lauro R, Federici M. Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. *Atherosclerosis*. 2011 Mar;215(1):180-3.
73. Bellia A, Garcovich C, D'Adamo M, Lombardo M, Tesauro M, Donadel G, Gentileschi P, Lauro D, Federici M, Lauro R, Sbraccia P. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. *Intern Emerg Med*. 2011 Mar 25.
74. Rizza S, Federici M. Cytokines and metabolic syndrome: the perfect storm for arterial aging. *Atherosclerosis*. 2011 Apr;215(2):284-5.
75. Iacobini C, Menini S, Ricci C, Blasetti Fantauzzi C, Scipioni A, Salvi L, Cordone S, Delucchi F, Serino M, Federici M, Pricci F, Pugliese G. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. *J Hepatol*. 2011 May;54(5):975-83.
76. Vasa-Nicotera M, Chen H, Tucci P, Yang AL, Saintigny G, Menghini R, Mahè C, Agostini M, Knight RA, Melino G, Federici M. miR-146a is modulated in human endothelial cell with aging. *Atherosclerosis*. 2011 Aug;217(2):326-30.
77. Menghini R, Federici M. MicroPPAR α in atherosclerosis: guilty or innocent by-standers? *Atherosclerosis*. 2011 Sep;218(1):21-2.
78. Lombardo MF, De Angelis F, Bova L, Bartolini B, Bertuzzi F, Nano R, Capuani B, Lauro R, Federici M, Lauro D, Donadel G. Human placental lactogen (hPL-A) activates signaling pathways linked to cell survival and improves insulin secretion in human pancreatic islets. *Islets*. 2011 Sep-Oct;3(5):250-8. 2011 Aug;217(2):326-30.

79. Avogaro A, Federici M, Betteridge J, Bonadonna R, Campbell IW, Scherthaner GH, Staels B, Farinara E, Crepaldi G. Which is the eligible patient to be treated with pioglitazone? The expert view. *J Endocrinol Invest*. 2011 Nov;34(10):781-7.
80. Cardellini M, Menghini R, Luzi A, Davato F, Cardolini I, D'Alfonso R, Gentileschi P, Rizza S, Marini MA, Porzio O, Lauro D, Sbraccia P, Lauro R, Federici M. Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness. *Diabetes*. 2011 Dec;60(12):3265-70.
81. Marchetti C, Di Carlo A, Facchiano F, Senatore C, De Cristofaro R, Luzi A, Federici M, Romani M, Napolitano M, Capogrossi MC, Germani A. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. *Diabetologia*. 2012 Jan;55(1):236-44.
82. Casagrande V, Menghini R, Menini S, Marino A, Marchetti V, Cavalera M, Fabrizi M, Hribal ML, Pugliese G, Gentileschi P, Schillaci O, Porzio O, Lauro D, Sbraccia P, Lauro R, Federici M. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. *Arterioscler Thromb Vasc Biol*. 2012 Jan;32(1):74-81.
83. Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, Lauro D, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, Federici M. TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. *Diabetes*. 2012 Feb;61(2):454-62.
84. Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, Quon MJ, Sbraccia P, Federici M, Tesaro M, Cardillo C, Lauro D. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. *Atherosclerosis*. 2012 Jul;223(1):197-203.
85. Rizza S, Copetti M, Cardellini M, Porzio O, Luzi A, Pecchioli C, Martelli E, Valentini A, Ippoliti A, Romeo F, Pellegrini F, Lauro D, Lauro R, Federici M. Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention. *Atherosclerosis*. 2012 Aug;223(2):448-53.
86. Stoehr R, Federici M. Do stem cells cause aging-related intimal medial thickening? *Atherosclerosis*. 2012 Sep;224(1):39-40.
87. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A, Federici M, Dinsdale D, Knight RA, Melino G, Mak TW. TAp73 depletion accelerates aging through metabolic dysregulation. *Genes Dev*. 2012 Sep 15;26(18):2009-14.
88. Monteleone I, Federici M, Sarra M, Franzè E, Casagrande V, Zorzi F, Cavalera M, Rizzo A, Lauro R, Pallone F, MacDonald TT, Monteleone G. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. *Gastroenterology*. 2012 Nov;143(5):1277-87.
89. Bellia A, Marinoni G, D'Adamo M, Guglielmi V, Lombardo M, Donadel G, Gentileschi P, Lauro D, Federici M, Lauro R, Sbraccia P. Parathyroid hormone and insulin resistance in distinct phenotypes of severe obesity: a cross-sectional analysis in middle-aged men and premenopausal women. *J Clin Endocrinol Metab*. 2012 Dec;97(12):4724-32.
90. Bacci S, Prudente S, Copetti M, Spoto B, Rizza S, Baratta R, Di Pietro N, Morini E, Di Paola R, Testa A, Mallamaci F, Tripepi G, Zhang YY, Mercuri L, Di Silvestre S, Lauro R, Malatino L, Consoli A, Pellegrini F, Pandolfi A, Frittitta L, Zoccali C, Federici M, Doria A, Trischitta V. Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance. *Atherosclerosis*. 2013 Jan;226(1):140-5.
91. Rappa, F, Greco, A, Podrini, C, Cappello, F, Foti, M, Bourgojn, L, Peyrou, M, Marino, A, Scibetta, N, Williams, R, Mazzocchi, G, Federici, M, Pazienza, V, Vinciguerra, M. Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma. *PLoS One*. 2013;8(1):e54458. doi: 10.1371/journal.pone.005445
92. Fiorentino L, Cavalera M, Menini S, Marchetti V, Mavilio M, Fabrizi M, Conserva F, Casagrande V, Menghini R, Pontrelli P, Arisi I, D'Onofrio M, Lauro D, Khokha R, Accili D, Pugliese G, Gesualdo L, Lauro R, Federici M. Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay. *EMBO MOLECULAR MEDICINE* 2013 Mar;5(3):441-55
93. Menghini R, Fiorentino L, Casagrande V, Lauro R, Federici M. The role of ADAM17 in Metabolic Inflammation. *Atherosclerosis* 2013 6.487May;228(1):12-7.
94. Menghini R, Uccioli L, Vainieri E, Pecchioli C, Casagrande V, Stoehr R, Cardellini M, Porzio O, Rizza S, Federici M. Expression of tissue inhibitor of metalloprotease 3 is reduced in ischemic but not neuropathic ulcers from patients with type 2 diabetes mellitus. *Acta Diabetol*. 2013 Dec;50(6):907-10
95. Avogaro A, Vigili de Kreutzenberg S, Federici M, Fadini GP. The Endothelium abridges Insulin Resistance to Premature Ageing. *J Am Heart Assoc*. 2013 Jun 21;2(3):e000262
96. Menghini R, Casagrande V, Lauro R, Federici M. MicroRNAs in endothelial senescence and atherosclerosis *Journal of Cardiovascular Translational Research* 2013 Dec;6(6):924-30
97. Fiorentino L, Cavalera M, Mavilio M, Conserva F, Menghini R, Gesualdo L, Federici M. Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs. *Acta Diabetol*. 2013 Dec;50(6):965-9.

98. Menzaghi C, Bacci S, Salvemini L, Mendonca C, Palladino G, Fontana A, De Bonis C, Marucci A, Goheen E, Prudente S, Morini E, Rizza S, Kanagaki A, Fini G, Mangiacotti D, Federici M, De Cosmo S, Pellegrini F, Doria A, Trischitta V. Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. *PLoS One*. 2013 Jun 3;8(6):e64729.
99. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. *Diabetologia*. 2013 Oct;56(10):2153-63
100. Stoehr R, Federici M. Insulin resistance and atherosclerosis: convergence between metabolic pathways and inflammatory nodes. *Biochem J*. 2013 Aug 15;454(1):1-11
101. Saraceno R, Rizza S, Faleri S, Federici M, Nistico SP, Copetti M, Chimenti S. High density cholesterol level as predictor of clinical response to anti-TNF-alpha therapy in psoriatic patients. *J Biol Regul Homeost Agents*. 2013 Jul-Sep;27(3):903-8.
102. Marino A, Menghini R, Fabrizi M, Casagrande V, Mavilio M, Stoehr R, Candi E, Mauriello A, Moreno-Navarrete JM, Gómez-Serrano M, Peral B, Melino G, Lauro R, Fernandez Real JM, Federici M. ITC deficiency protects from diet-induced obesity. *Diabetes*. 2014 Feb;63(2):550-61.
103. Bellia A, Salli M, Lombardo M, D'Adamo M, Guglielmi V, Tirabasso C, Giordani L, Federici M, Lauro D, Foti C, Sbraccia P. Effects of Whole Body Vibration Plus Diet on Insulin-Resistance in Middle-Aged Obese Subjects. *Int J Sports Med*. 2014 Jun;35(6):511-6.
104. Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, Federici M, Van Tassell BW, Zhang S, Abbate A. A NOVEL PHARMACOLOGIC INHIBITOR OF THE NLRP3 INFLAMMASOME LIMITS MYOCARDIAL INJURY FOLLOWING ISCHEMIA-REPERFUSION IN THE MOUSE. *J Cardiovasc Pharmacol*. 2014 Apr;63(4):316-22.
105. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, Andreozzi F, Jenkinson C, Cersosimo E, Federici M, Tripathy D, Folli F. The inflammatory status score including IL-6, TNF- α , osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. *Acta Diabetol*. 2014 Feb;51(1):123-31.
106. Stöhr R, Marx N, Federici M. Tick-tock: Is your cardiometabolic risk on the clock? *Diab Vasc Dis Res*. 2014 Mar;11(2):66-74.
107. Fabrizi M, Marchetti V, Mavilio M, Marino A, Casagrande V, Cavallera M, Moreno Navarrete JM, Mezza T, Sorice GP, Fiorentino L, Menghini R, Lauro R, Monteleone G, Giaccari A, Fernandez Real JM, Federici M. IL-21 is a major negative regulator of IRF4-dependent lipolysis affecting Tregs in adipose tissue and systemic insulin sensitivity. *Diabetes*. 2014 Jun;63(6):2086-96
108. Menghini R, Stöhr R, Federici M. MicroRNAs in vascular aging and atherosclerosis. *Ageing Res Rev*. 2014 Mar 27.
109. Menghini R, Casagrande V, Marino A, Marchetti V, Cardellini M, Stoehr R, Rizza S, Martelli E, Greco S, Mauriello A, Ippoliti A, Martelli F, Lauro R, Federici M. MiR-216a: a link between endothelial dysfunction and autophagy. *Cell Death Dis*. 2014 Jan 30;5:e1029.
110. Rizza S, Copetti M, Rossi C, Cianfarani MA, Zucchelli M, Luzi A, Pecchioli C, Porzio O, Di Cola G, Urbani A, Pellegrini F, Federici M. Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. *Atherosclerosis*. 2014 Feb;232(2):260-4.
111. Menghini R, Campia U, Tesaro M, Marino A, Rovella V, Rodia G, Schinzari F, Tolusso B, di Daniele N, Federici M, Zoli A, Ferraccioli G, Cardillo C. Toll-Like Receptor 4 Mediates Endothelial Cell Activation Through NF- κ B but Is Not Associated with Endothelial Dysfunction in Patients with Rheumatoid Arthritis. *PLoS One*. 2014 Jun 11;9(6):e99053.
112. Stöhr R, Cavallera M, Menini S, Mavilio M, Casagrande V, Rossi C, Urbani A, Cardellini M, Pugliese G, Menghini R, Federici M. Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice. *Atherosclerosis*. 2014 Jun 4;235(2):438-443
113. Pacifici F, Arriga R, Sorice GP, Capuani B, Scioli MG, Pastore D, Donadel G, Bellia A, Caratelli S, Coppola A, Ferrelli F, Federici M, Sconocchia G, Tesaro M, Sbraccia P, Della-Morte D, Giaccari A, Orlandi A, Lauro D. Peroxiredoxin 6, a Novel Player in the Pathogenesis of Diabetes. *Diabetes*. 2014 Jun 19. pii: DB_140144. [Epub ahead of print] PubMed PMID: 24947358.
114. Ferrelli F, Pastore D, Capuani B, Lombardo MF, Blot-Chabaud M, Coppola A, Basello K, Galli A, Donadel G, Romano M, Caratelli S, Pacifici F, Arriga R, Di Daniele N, Sbraccia P, Sconocchia G, Bellia A, Tesaro M, Federici M, Della-Morte D, Lauro D. Serum glucocorticoid inducible kinase (SGK)-1 protects endothelial cells against oxidative stress and apoptosis induced by hyperglycaemia. *Acta Diabetol*. 2014 Jun 25. [Epub ahead of print] PubMed PMID: 24961472.
115. Guglielmi V, Maresca L, D'Adamo M, Di Roma M, Lanzillo C, Federici M, Lauro D, Preziosi P, Bellia A, Sbraccia P. Age-related different relationships between ectopic adipose tissues and measures of central obesity in sedentary subjects. *PLoS One*. 2014 Jul 22;9(7):e103381.

- 116.Menzaghi C, Fontana A, Copetti M, Rizza S, Spoto B, Buranasupkajorn P, Tripepi, Marucci A, Bailetti D, Hastings T, Testa A, Mendonca C, Mallamaci F, De Cosmo S, Bacci S, Federici M, Doria A, Zoccali C, Trischitta V. Joint effect of insulin signaling genes on all-cause mortality. *Atherosclerosis*. 2014 Dec;237(2):639-44.
- 117.Kappel BA, Federici M. Can renin inhibition by Aliskiren prove itself in atherosclerosis prevention? *Atherosclerosis*. 2014 Dec;237(2):767-8.
- 118.Puig J, Blasco G, Daunis-I-Estadella J, Loshuertos E, Codina J, Cuba V, Ortiz R, Xifra G, Ricart W, Pedraza S, Federici M, Fernández-Real JM. Nonalcoholic fatty liver disease and age are strong indicators for atherosclerosis in morbid obesity. *Clin Endocrinol (Oxf)*. 2014 Dec 16. doi: 10.1111/cen.12698.
- 119.Carnevale D, Pallante F, Fardella V, Fardella S, Iacobucci R, Federici M, Cifelli G, De Lucia M, Lembo G. The angiogenic factor PlGF mediates a neuroimmune interaction in the spleen to allow the onset of hypertension. *Immunity*. 2014 Nov 20;41(5):737-52.
- 120.Federici M. Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome. *Atheroscler Suppl*. 2015 Feb;17:17-22.
- 121.Rizza S, Copetti M, Cardellini M, Menghini R, Pecchioli C, Luzi A, Di Cola G, Porzio O, Ippoliti A, Romeo F, Pellegrini F, Federici M. A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis. *Atherosclerosis*. 2015 Apr;239(2):459-64.
- 122.Capuani B, Della-Morte D, Donadel G, Caratelli S, Bova L, Pastore D, De Canio M, D'Aguanno S, Coppola A, Pacifici F, Arriga R, Bellia A, Ferrelli F, Tesauro M, Federici M, Neri A, Bernardini S, Sbraccia P, Di Daniele N, Sconocchia G, Orlandi A, Urbani A, Lauro D. Liver Protein Profiles in Insulin Receptor Knockout Mice Reveal Novel Molecules Involved in the Diabetes Pathophysiology. *Am J Physiol Endocrinol Metab*. 2015 Feb 24;ajpendo.00447.2014. doi: 10.1152/ajpendo.00447.2014.
- 123.Stöhr R, Mavilio M, Marino A, Casagrande V, Kappel B, Möllmann J, Menghini R, Melino G, Federici M. ITC modulates SIRT6 and SREBP2 to influence lipid metabolism and atherosclerosis in ApoE null mice. *Sci Rep*. 2015 Mar 17;5:9023. doi: 10.1038/srep09023.
- 124.Luzi A, Rizza S, Cardellini M, Pecchioli C, Di Cola G, Davato F, Porzio O, Ippoliti A, Copetti M, Federici M. A1c value for diabetes diagnosis in subjects with established cardiovascular disease. *Acta Diabetol*. 2015 Mar 27. [Epub ahead of print] PubMed PMID: 25813366.
- 125.Lauro D, Pastore D, Capuani B, Pacifici F, Palmirotta R, Abete P, Roselli M, Bellia A, Federici M, Di Daniele N, Sbraccia P, Guadagni F, Lauro R, Della-Morte D. Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: a Novel Molecular Target against Age-Related Diseases. *Curr Med Chem*. 2015 Aug 12. [Epub ahead of print] PubMed PMID: 26264924.
- 126.Guglielmi V, Cardellini M, Cinti F, Corgosinho F, Cardolini I, D'Adamo M, Zingaretti MC, Bellia A, Lauro D, Gentileschi P, Federici M, Cinti S, Sbraccia P. Omental adipose tissue fibrosis and insulin resistance in severe obesity. *Nutr Diabetes*. 2015 Aug 10;5:e175. doi: 10.1038/nutd.2015.22. PubMed PMID: 26258766.
- 127.Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, Sconocchia G, Bellia A, Rogliani P, Federici M, Sbraccia P, Lauro D, Della-Morte D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT. *Rejuvenation Res*. 2015 Jul 31. [Epub ahead of print] PubMed PMID: 26230157.
- 128.Menghini R, Casagrande V, Cardellini M, Ballanti M, Davato F, Cardolini I, Stoehr R, Fabrizi M, Morelli M, Anemona L, Bernges I, Schwedhelm E, Ippoliti A, Mauriello A, Böger RH, Federici M. FoxO1 regulates asymmetric dimethylarginine via downregulation of dimethylaminohydrolase 1 in human endothelial cells and subjects with atherosclerosis. *Atherosclerosis*. 2015 Sep;242(1):230-5.
- 129.Kappel BA, Marx N, Federici M. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. *Nutr Metab Cardiovasc Dis*. 2015 Aug;25(8):697-705.
- 130.Marchetti C, Toldo S, Chojnacki J, Mezzaroma E, Liu K, Salloum FN, Nordio A, Carbone S, Mauro AG, Das A, Zalavadia AA, Halquist MS, Federici M, Van Tassell BW, Zhang S, Abbate A. Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. *J Cardiovasc Pharmacol*. 2015 Jul;66(1):1-8.
- 131.Guglielmi V, D'Adamo M, Bellia A, Ciotto RT, Federici M, Lauro D, Sbraccia P. Iron status in obesity: An independent association with metabolic parameters and effect of weight loss. *Nutr Metab Cardiovasc Dis*. 2015 Jun;25(6):541-7.
- 132.Pastore D, Della-Morte D, Coppola A, Capuani B, Lombardo MF, Pacifici F, Ferrelli F, Arriga R, Mammi C, Federici M, Bellia A, Di Daniele N, Tesauro M, Donadel G, Noto D, Sbraccia P, Sconocchia G, Lauro D. SGK-1 protects kidney cells against apoptosis induced by ceramide and TNF- α . *Cell Death Dis*. 2015 Sep 17;6:e1890.
- 133.Stöhr R, Kappel BA, Carnevale D, Cavallera M, Mavilio M, Arisi I, Fardella V, Cifelli G, Casagrande V, Rizza S, Cattaneo A, Mauriello A, Menghini R, Lembo G, Federici M. TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice. *Mol Metab*. 2015 Aug 6;4(10):741-52.
- 134.Testa A, Prudente S, Leonardis D, Spoto B, Sanguedolce MC, Parlongo RM, Tripepi G, Rizza S, Mallamaci F, Federici M, Trischitta V, Zoccali C. A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. *Nutr Metab Cardiovasc Dis*. 2015 Aug 21

135. Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356.
136. Bessar H, Venditti I, Benassi L, Vaschieri C, Azzoni P, Pellacani G, Magnoni C, Botti E, Casagrande V, Federici M, Costanzo A, Fontana L, Testa G, Mostafa FF, Ibrahim SA, Russo MV, Fratoddi I. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. *Colloids Surf B Biointerfaces*. 2016 May 1;141:141-7. doi: 10.1016/j.colsurfb.2016.01.021.
137. Kappel BA, Stöhr R, De Angelis L, Mavilio M, Menghini R, Federici M. Posttranslational modulation of FoxO1 contributes to cardiac remodeling in post-ischemic heart failure. *Atherosclerosis*. 2016 Jun;249:148-56. doi: 10.1016/j.atherosclerosis.2016.04.001.
138. Savarese G, D'Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. *Int J Cardiol*. 2016 Jun 27;220:595-601. doi: 10.1016/j.ijcard.2016.06.208.
139. Fryk E, Sundelin JP, Strindberg L, Pereira MJ, Federici M, Marx N, Nyström FH, Schmelz M, Svensson PA, Eriksson JW, Borén J, Jansson PA. Microdialysis and proteomics of subcutaneous interstitial fluid reveals increased galectin-1 in type 2 diabetes patients. *Metabolism*. 2016 Jul;65(7):998-1006. doi: 10.1016/j.metabol.2016.04.003.
140. Mavilio M, Marchetti V, Fabrizi M, Stöhr R, Marino A, Casagrande V, Fiorentino L, Cardellini M, Kappel B, Monteleone I, Garret C, Mauriello A, Monteleone G, Farcomeni A, Burcelin R, Menghini R, Federici M. A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction. *Cell Rep*. 2016 Jun 29. pii: S2211-1247(16)30767-7. doi: 10.1016/j.celrep.2016.06.027.
141. Guglielmi V, Bellia A, Pecchioli S, Medea G, Parretti D, Lauro D, Sbraccia P, Federici M, Cricelli I, Cricelli C, Lapi F. What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database. *Int J Cardiol*. 2016 Nov 15;223:701-705. doi: 10.1016/j.ijcard.2016.08.269.
142. Lelouvier B, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. *Hepatology*. 2016 Dec;64(6):2015-2027. doi:10.1002/hep.28829.
143. Möllmann J, Kahles F, Lebherz C, Kappel B, Baek C, Tacke F, Werner C, Federici M, Marx N, Lehrke M. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. *Diabetes Obes Metab*. 2016 Dec 5. doi: 10.1111/dom.12839.
144. Bertoli A, Valentini A, Cianfarani MA, Gasbarra E, Tarantino U, Federici M. Low FT3: a possible marker of frailty in the elderly. *Clin Interv Aging*. 2017 Feb 10;12:335-341.
145. Guglielmi V, D'Adamo M, Menghini R, Cardellini M, Gentileschi P, Federici M, Sbraccia P. MicroRNA 21 is up-regulated in adipose tissue of obese diabetic subjects. *Nutr Healthy Aging*. 2017 Mar 31;4(2):141-145.
146. Cardellini M, Farcomeni A, Ballanti M, Morelli M, Davato F, Cardolini I, Grappasonni G, Rizza S, Guglielmi V, Porzio O, Pecchioli C, Menghini R, Ippoliti A, Federici M. C-peptide: A predictor of cardiovascular mortality in subjects with established atherosclerotic disease. *Diab Vasc Dis Res*. 2017 May 1;1479164117710446. doi: 10.1177/1479164117710446.
147. Bischetti S, Scimeca M, Bonanno E, Federici M, Anemona L, Menghini R, Casella S, Cardellini M, Ippoliti A, Mauriello A. Carotid plaque instability is not related to quantity but to elemental composition of calcification. *Nutr Metab Cardiovasc Dis*. 2017 May 31. pii: S0939-4753(17)30116-3.
148. Casagrande V, Mauriello A, Bischetti S, Mavilio M, Federici M, Menghini R. Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma. *Sci Rep*. 2017 Jul 27;7(1):6747.
149. Moreno-Navarrete JM, Serino M, Blasco-Baque V, Azalbert V, Barton RH, Cardellini M, Latorre J, Ortega F, Sabater-Masdeu M, Burcelin R, Dumas ME, Ricart W, Federici M, Fernández-Real JM. Gut Microbiota Interacts with Markers of Adipose Tissue Browning, Insulin Action and Plasma Acetate in Morbid Obesity. *Mol Nutr Food Res*. 2018 Feb;62(3). doi: 10.1002/mnfr.201700721.
150. Rossi C, Marzano V, Consalvo A, Zucchelli M, Levi Mortera S, Casagrande V, Mavilio M, Sacchetta P, Federici M, Menghini R, Urbani A, Ciavardelli D. Proteomic and metabolomic characterization of streptozotocin-induced diabetic nephropathy in TIMP3-deficient mice. *Acta Diabetol*. 2018 Feb;55(2):121-129. doi: 10.1007/s00592-017-1074-y.
151. Rizza S, Cardellini M, Piciocchi G, Longo S, Guglielmi V, Tesaro M, Di Cola G, Pecchioli C, Federici M. Brachial flow-mediated dilation predicts glycemia worsening in normoglycemic young subjects. *Acta Diabetol*. 2018 Apr;55(4):387-389. doi: 10.1007/s00592-018-1108-0.
152. Brachial flow-mediated dilation predicts glycemia worsening in normoglycemic young subjects. Rizza S, Cardellini M, Piciocchi G, Longo S, Guglielmi V, Tesaro M, Di Cola G, Pecchioli

- C, Federici M. *Acta Diabetol.* 2018 Apr;55(4):387-389. doi: 10.1007/s00592-018-1108-0. Epub 2018 Feb 26. PMID: 29480336 No abstract available.
153. The role of obesity in carotid plaque instability: interaction with age, gender, and cardiovascular risk factors. Rovella V, Anemona L, Cardellini M, Scimeca M, Saggini A, Santeusano G, Bonanno E, Montanaro M, Legramante IM, Ippoliti A, Di Daniele N, Federici M, Mauriello A. *Cardiovasc Diabetol.* 2018 Mar 29;17(1):46. doi: 10.1186/s12933-018-0685-0. PMID: 29598820 Free PMC article.
 154. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, Sovran B, Denis RGP, Dairou J, Cardellini M, Moreno-Navarrete JM, Straub M, Jegou S, McQuitty C, Viel T, Esposito B, Tavitian B, Callebort J, Luquet SH, Federici M, Fernandez-Real JM, Burcelin R, Launay JM, Tedgui A, Mallat Z, Sokol H, Taleb S. *Nat Med.* 2018 Aug;24(8):1113-1120. doi: 10.1038/s41591-018-0060-4. Epub 2018 Jun 25. PMID: 29942089
 155. 2-hydroxycaproate predicts cardiovascular mortality in patients with atherosclerotic disease. Cardellini M, Ballanti M, Davato F, Cardolini I, Guglielmi V, Rizza S, Pecchioli C, Casagrande V, Mavilio M, Porzio O, Legramante JM, Ippoliti A, Farcomeni A, Sbraccia P, Menghini R, Dumas ME, Kappel BA, Federici M. *Atherosclerosis.* 2018 Oct;277:179-185. doi: 10.1016/j.atherosclerosis.2018.06.014. Epub 2018 Jun 12. PMID: 29958653
 156. FRAX tool in type 2 diabetic subjects: the use of HbA1c in estimating fracture risk. Valentini A, Cianfarani MA, De Meo L, Morabito P, Romanello D, Tarantino U, Federici M, Bertoli A. *Acta Diabetol.* 2018 Oct;55(10):1043-1050. doi: 10.1007/s00592-018-1187-y. Epub 2018 Jul 6. PMID: 29980834
 157. Frailty and nutritional status in older people: the Mini Nutritional Assessment as a screening tool for the identification of frail subjects. Valentini A, Federici M, Cianfarani MA, Tarantino U, Bertoli A. *Clin Interv Aging.* 2018 Jul 13;13:1237-1244. doi: 10.2147/CIA.S164174. eCollection 2018. PMID: 30034227 Free PMC article.
 158. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects. Cardellini M, Rizza S, Casagrande V, Cardolini I, Ballanti M, Davato F, Porzio O, Canale MP, Legramante JM, Mavilio M, Menghini R, Martelli E, Farcomeni A, Federici M. *Acta Diabetol.* 2019 Mar;56(3):273-280. doi: 10.1007/s00592-018-1230-z. Epub 2018 Sep 26. PMID: 30259114
 159. Low Molecular Weight Adiponectin Increases the Mortality Risk in Very Old Patients. Rizza S, Cardellini M, Farcomeni A, Morabito P, Romanello D, Di Cola G, Canale MP, Federici M. *Aging Dis.* 2018 Oct 1;9(5):946-951. doi: 10.14336/AD.2017.1117. eCollection 2018 Oct. PMID: 30271669 Free PMC article.
 160. Metabolically healthy versus metabolically unhealthy obesity. Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. *Metabolism.* 2019 Mar;92:51-60. doi: 10.1016/j.metabol.2018.11.009. Epub 2018 Nov 17. PMID: 30458177 Review.
 161. MicroRNA 221/222 cluster kicks out Timp-3 to inflame the liver. Menghini R, Federici M. *EBioMedicine.* 2018 Nov;37:7-8. doi: 10.1016/j.ebiom.2018.10.040. Epub 2018 Oct 19. PMID: 30344123 Free PMC article. No abstract available.
 162. MicroRNA Manipulation to Boost Endothelial Regeneration: Are We Ready for the Next Steps? Menghini R, Federici M. *Diabetes.* 2019 Feb;68(2):268-270. doi: 10.2337/dbi18-0044. PMID: 30665956 No abstract available.
 163. Chronic Kidney Disease Is Linked to Carotid Nodular Calcification, An Unstable Plaque Not Correlated to Inflammation. Cardellini M, Rovella V, Scimeca M, Anemona L, Bischetti S, Casella S, Saggini A, Bonanno E, Ballanti M, Davato F, Menghini R, Ippoliti A, Santeusano G, Di Daniele N, Federici M, Mauriello A. *Aging Dis.* 2019 Feb 1;10(1):71-81. doi: 10.14336/AD.2018.0117. eCollection 2019 Feb. PMID: 30705769 Free PMC article.
 164. The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stress-Driven Mucus Depletion and Exacerbates Intestinal Inflammation. Laudisi F, Di Fusco D, Dinallo V, Stolfi C, Di Grazia A, Marafini I, Colantoni A, Ortenzi A, Alteri C, Guerrieri F, Mavilio M, Ceccherini-Silberstein F, Federici M, MacDonald TT, Monteleone I, Monteleone G. *Cell Mol Gastroenterol Hepatol.* 2019;7(2):457-473. doi: 10.1016/j.jcmgh.2018.09.002. Epub 2018 Sep 11. PMID: 30765332 Free PMC article.

165. Gut microbiome and microbial metabolites: a new system affecting metabolic disorders. Federici M. *J Endocrinol Invest*. 2019 Sep;42(9):1011-1018. doi: 10.1007/s40618-019-01022-9. Epub 2019 Feb 20. PMID: 30788772 Review.
166. Our second genome and the impact on metabolic disorders: why gut microbiome is an important player in diabetes and associated abnormalities. Federici M. *Acta Diabetol*. 2019 May;56(5):491-492. doi: 10.1007/s00592-019-01315-8. Epub 2019 Mar 25. PMID: 30906973 No abstract available.
167. Timp3 deficiency affects the progression of DEN-related hepatocellular carcinoma during diet-induced obesity in mice. Casagrande V, Mauriello A, Anemona L, Mavilio M, Iuliani G, De Angelis L, D'Onofrio M, Arisi I, Federici M, Menghini R. *Acta Diabetol*. 2019 Dec;56(12):1265-1274. doi: 10.1007/s00592-019-01382-x. Epub 2019 Jul 10. PMID: 31292722
168. Climate changes and ST-elevation myocardial infarction treated with primary percutaneous coronary angioplasty. Versaci F, Biondi-Zoccai G, Giudici AD, Mariano E, Trivisonno A, Sciarretta S, Valenti V, Peruzzi M, Cavarretta E, Frati G, Scappaticci M, Federici M, Romeo F. *Int J Cardiol*. 2019 Nov 1;294:1-5. doi: 10.1016/j.ijcard.2019.07.006. Epub 2019 Jul 3. PMID: 31301864
169. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. *Eur Heart J*. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486. PMID: 31497854 Review. No abstract available.
170. Night Shift Working Is Associated With an Increased Risk of Thyroid Nodules. Rizza S, Neri A, Capanna A, Grecuccio C, Pietroiusti A, Magrini A, Federici M, Coppeta L. *J Occup Environ Med*. 2020 Jan;62(1):1-3. doi: 10.1097/JOM.0000000000001711. PMID: 31626062
171. Osteoprotegerin in diabetic osteopathy. Valentini A, Cianfarani MA, Federici M, Tarantino U, Bertoli A. *Nutr Metab Cardiovasc Dis*. 2020 Jan 3;30(1):49-55. doi: 10.1016/j.numecd.2019.08.018. Epub 2019 Sep 9. PMID: 31757570
172. Metabolic aspects of cardiovascular diseases: Is FoxO1 a player or a target? Menghini R, Casagrande V, Iuliani G, Rizza S, Mavilio M, Cardellini M, Federici M. *Int J Biochem Cell Biol*. 2020 Jan;118:105659. doi: 10.1016/j.biocel.2019.105659. Epub 2019 Nov 22. PMID: 31765819 Review.
173. Gut microbiome and cardiometabolic risk. Kappel BA, Federici M. *Rev Endocr Metab Disord*. 2019 Dec;20(4):399-406. doi: 10.1007/s11154-019-09533-9. PMID: 31836950 Review.
174. Consider the microbiome in the equation! They were here before us...and hosted us! Fernández-Real JM, Federici M, Burcelin R. *Rev Endocr Metab Disord*. 2019 Dec;20(4):383-385. doi: 10.1007/s11154-019-09538-4. PMID: 31865508 No abstract available.
175. Frataxin deficiency induces lipid accumulation and affects thermogenesis in brown adipose tissue. Turchi R, Tortolici F, Guidobaldi G, Iacovelli F, Falconi M, Rufini S, Faraonio R, Casagrande V, Federici M, De Angelis L, Carotti S, Francesconi M, Zingariello M, Morini S, Bernardini R, Mattei M, La Rosa P, Piemonte F, Lettieri-Barbato D, Aquilano K. *Cell Death Dis*. 2020 Jan 23;11(1):51. doi: 10.1038/s41419-020-2253-2. PMID: 31974344 Free PMC article.
176. Diabetes influences cancer risk in patients with increased carotid atherosclerosis burden. Rizza S, Rossini V, Cardellini M, Luzi A, Longo S, Piciocchi G, Coppeta L, Federici M. *Nutr Metab Cardiovasc Dis*. 2020 Apr 12;30(4):652-655. doi: 10.1016/j.numecd.2019.11.016. Epub 2019 Dec 10. PMID: 32007331
177. The APOA1bp-SREBF-NOTCH axis is associated with reduced atherosclerosis risk in morbidly obese patients. Mayneris-Perxachs J, Puig J, Burcelin R, Dumas ME, Barton RH, Hoyles L, Federici M, Fernández-Real JM. *Clin Nutr*. 2020 Nov;39(11):3408-3418. doi: 10.1016/j.clnu.2020.02.034. Epub 2020 Mar 8. PMID: 32199697
178. Venous distal bypass should be considered as the gold standard to finally attempt limb salvage in patients with severe critical limb ischemia and diabetic foot, or under dialysis. Martelli E, Federici M. *Acta Diabetol*. 2020 Aug;57(8):1019-1020. doi: 10.1007/s00592-020-01524-6. Epub 2020 Apr 3. PMID: 32246269 No abstract available.

179. Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. Kappel BA, De Angelis L, Heiser M, Ballanti M, Stoeck R, Goettsch C, Mavilio M, Artati A, Paoluzi OA, Adamski J, Mingrone G, Staels B, Burcelin R, Monteleone G, Menghini R, Marx N, Federici M. *Mol Metab*. 2020 Jun;36:100976. doi: 10.1016/j.molmet.2020.100976. Epub 2020 Mar 13. PMID: 32251665 Free PMC article.
180. Monthly fluctuations in 25-hydroxy-vitamin D levels in day and rotating night shift hospital workers. Rizza S, Pietroiusti A, Farcomeni A, Mina GG, Caruso M, Virgilio M, Magrini A, Federici M, Coppeta L. *J Endocrinol Invest*. 2020 Nov;43(11):1655-1660. doi: 10.1007/s40618-020-01265-x. Epub 2020 Apr 27. PMID: 32342444
181. Does bronchoscopy help the diagnosis in COVID-19 infection? Ora J, Puxeddu E, Cavalli F, Giorgino FM, Girolami A, Chiocchi M, Sergiacomi G, Federici M, Rogliani P. *Eur Respir J*. 2020 Aug 6;56(2):2001619. doi: 10.1183/13993003.01619-2020. Print 2020 Aug. PMID: 32527742 Free PMC article.
182. Complete blood count might help to identify subjects with high probability of testing positive to SARS-CoV-2. Formica V, Minieri M, Bernardini S, Ciotti M, D'Agostini C, Roselli M, Andreoni M, Morelli C, Parisi G, Federici M, Paganelli C, Legramante JM. *Clin Med (Lond)*. 2020 Jul;20(4):e114-e119. doi: 10.7861/clinmed.2020-0373. Epub 2020 Jul 2. PMID: 32620590 Free PMC article.
183. Carotid intimal medial thickness in rotating night shift is related to IL1 β /IL6 axis. Rizza S, Longo S, Piciucchi G, Romanello D, Mavilio M, Montagna M, Coppeta L, Martelli E, Magrini A, Federici M. *Nutr Metab Cardiovasc Dis*. 2020 Sep 24;30(10):1826-1832. doi: 10.1016/j.numecd.2020.05.028. Epub 2020 Jun 7. PMID: 32665209
184. Bariatric Surgery-Induced Changes in Intima-Media Thickness and Cardiovascular Risk Factors in Class 3 Obesity: A 3-Year Follow-Up Study. Domenech-Ximenes B, Cuba V, Daunis-I-Estadella P, Thió-Henestrosa S, Jaldo F, Biarnes C, Molina X, Xifra G, Ricart W, Bardera A, Boada I, Essig M, Pedraza S, Federici M, Fernández-Real JM, Puig J. *Obesity (Silver Spring)*. 2020 Sep;28(9):1663-1670. doi: 10.1002/oby.22905. Epub 2020 Aug 9. PMID: 32776483
185. High body mass index and night shift work are associated with COVID-19 in health care workers. Rizza S, Coppeta L, Girelli S, Ferrazza G, Chiocchi M, Vanni G, Bonomo OC, Bellia A, Andreoni M, Magrini A, Federici M. *J Endocrinol Invest*. 2021 May;44(5):1097-1101. doi: 10.1007/s40618-020-01397-0. Epub 2020 Aug 27. PMID: 32852704 Free PMC article.
186. Timed physical exercise does not influence circadian rhythms and glucose tolerance in rotating night shift workers: The EuRhythDia study. Hannemann J, Laing A, Glismann K, Skene DJ, Middleton B, Staels B, Marx N, Grant PJ, Federici M, Niebauer J, Böger R. *Diab Vasc Dis Res*. 2020 May-Jun;17(5):1479164120950616. doi: 10.1177/1479164120950616. PMID: 32975131 Free PMC article. Clinical Trial.
187. Cutaneous and metabolic defects associated with nuclear abnormalities in a transgenic mouse model expressing R527H lamin A mutation causing mandibuloacral dysplasia type A (MADA) syndrome. D'Apice MR, De Dominicis A, Murdocca M, Amati F, Botta A, Sangiuolo F, Lattanzi G, Federici M, Novelli G. *Acta Myol*. 2020 Dec 1;39(4):320-335. doi: 10.36185/2532-1900-036. eCollection 2020 Dec. PMID: 33458588 Free PMC article.
188. Restoration of renal TIMP3 levels via genetics and pharmacological approach prevents experimental diabetic nephropathy. Casagrande V, Iuliani G, Menini S, Pugliese G, Federici M, Menghini R. *Clin Transl Med*. 2021 Feb;11(2):e305. doi: 10.1002/ctm2.305. PMID: 33634991 Free PMC article.
189. Light therapy improves diurnal blood pressure control in night shift workers via reduction of catecholamines: the EuRhythDia study. Hannemann J, Laing A, Middleton B, Cridland J, Staels B, Marx N, Grant PJ, Federici M, Stenberg T, Skene DJ, Böger R. *J Hypertens*. 2021 Aug 1;39(8):1678-1688. doi: 10.1097/HJH.0000000000002848. PMID: 33710166
190. Alterations in Rev-ERB α /BMAL1 ratio and glycated hemoglobin in rotating shift workers: the EuRhythDia study. Rizza S, Luzi A, Mavilio M, Ballanti M, Massimi A, Porzio O, Magrini A, Hannemann J, Menghini R, Lehrke M, Staels B, Grant PJ, Boger RH, Marx N, Federici M. *Acta Diabetol*. 2021 Aug;58(8):1111-1117. doi: 10.1007/s00592-021-01676-z. Epub 2021 Mar 31. PMID: 33788000 Free PMC article.

191. IL-6 Levels Influence 3-Month All-Cause Mortality in Frail Hospitalized Older Patients. Rizza S, Morabito P, De Meo L, Farcomeni A, Testorio G, Cardellini M, Ballanti M, Davato F, Pecchioli C, Di Cola G, Mavilio M, Federici M. *Aging Dis.* 2021 Apr 1;12(2):353-359. doi: 10.14336/AD.2020.0713. eCollection 2021 Apr. PMID: 33815869 Free PMC article.
192. Gut Dysbiosis and Western Diet in the Pathogenesis of Essential Arterial Hypertension: A Narrative Review. Canale MP, Noce A, Di Lauro M, Marrone G, Cantelmo M, Cardillo C, Federici M, Di Daniele N, Tesaro M. *Nutrients.* 2021 Apr 1;13(4):1162. doi: 10.3390/nu13041162. PMID: 33915885 Free PMC article. Review.
193. Association of Urinary and Plasma Levels of Trimethylamine N-Oxide (TMAO) with Foods. Lombardo M, Aulisa G, Marcon D, Rizzo G, Tarsisano MG, Di Renzo L, Federici M, Caprio M, De Lorenzo A. *Nutrients.* 2021 Apr 23;13(5):1426. doi: 10.3390/nu13051426. PMID: 33922680 Free PMC article. Review.
194. The risk of carotid plaque instability in patients with metabolic syndrome is higher in women with hypertriglyceridemia. Servadei F, Anemona L, Cardellini M, Scimeca M, Montanaro M, Rovella V, Di Daniele F, Giacobbi E, Legramante IM, Noce A, Bonfiglio R, Borboni P, Di Daniele N, Ippoliti A, Federici M, Mauriello A. *Cardiovasc Diabetol.* 2021 May 6;20(1):98. doi: 10.1186/s12933-021-01277-8. PMID: 33957931 Free PMC article.
195. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Mayneris-Perxachs J, Cardellini M, Hoyles L, Latorre J, Davato F, Moreno-Navarrete JM, Arnoriaga-Rodríguez M, Serino M, Abbott J, Barton RH, Puig J, Fernández-Real X, Ricart W, Tomlinson C, Woodbridge M, Gentileschi P, Butcher SA, Holmes E, Nicholson JK, Pérez-Brocal V, Moya A, Clain DM, Burcelin R, Dumas ME, Federici M, Fernández-Real JM. *Microbiome.* 2021 May 7;9(1):104. doi: 10.1186/s40168-021-01052-7. PMID: 33962692 Free PMC article.
196. Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Avogaro A, Barillà F, Cavalot F, Consoli A, Federici M, Mancone M, Paolillo S, Pedrinelli R, Perseghin G, Perrone Filardi P, Scicali R, Sinagra G, Spaccarotella C, Indolfi C, Purrello F. *Nutr Metab Cardiovasc Dis.* 2021 Jun 7;31(6):1671-1690. doi: 10.1016/j.numecd.2021.02.029. Epub 2021 Mar 6. PMID: 33994263 Review.
197. Inhibition of Lysine 63 Ubiquitination Prevents the Progression of Renal Fibrosis in Diabetic DBA/2J Mice. Pontrelli P, Conserva F, Menghini R, Rossini M, Stasi A, Divella C, Casagrande V, Cinefra C, Barozzino M, Simone S, Pesce F, Castellano G, Stallone G, Gallone A, Giorgino F, Federici M, Gesualdo L. *Int J Mol Sci.* 2021 May 14;22(10):5194. doi: 10.3390/ijms22105194. PMID: 34068941 Free PMC article.
198. TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy. Casagrande V, Federici M, Menghini R. *Acta Diabetol.* 2021 Dec;58(12):1587-1594. doi: 10.1007/s00592-021-01766-y. Epub 2021 Jun 28. PMID: 34181080 Free PMC article. Review.
199. Human and mouse non-targeted metabolomics identify 1,5-anhydroglucitol as SGLT2-dependent glycemic marker. Kappel BA, Moellmann J, Thiele K, Rau M, Artati A, Adamski J, Ghesquiere B, Schuett K, Romeo F, Stoeckl R, Marx N, Federici M, Lehrke M. *Clin Transl Med.* 2021 Jun;11(6):e470. doi: 10.1002/ctm2.470. PMID: 34185398 Free PMC article. No abstract available.
200. A Serum Resistin and Multicytokine Inflammatory Pathway Is Linked With and Helps Predict All-cause Death in Diabetes. Scarale MG, Antonucci A, Cardellini M, Copetti M, Salvemini L, Menghini R, Mazza T, Casagrande V, Ferrazza G, Lamacchia O, De Cosmo S, Di Paola R, Federici M, Trischitta V, Menzaghi C. *J Clin Endocrinol Metab.* 2021 Oct 21;106(11):e4350-e4359. doi: 10.1210/clinem/dgab472. PMID: 34192323
201. The feeding behaviour of Amyotrophic Lateral Sclerosis mouse models is modulated by the Ca²⁺-activated KCa 3.1 channels. Coccozza G, Garofalo S, Morotti M, Chece G, Grimaldi A, Lecce M, Scavizzi F, Menghini R, Casagrande V, Federici M, Raspa M, Wulff H, Limatola C. *Br J Pharmacol.* 2021 Dec;178(24):4891-4906. doi: 10.1111/bph.15665. Epub 2021 Oct 5. PMID: 34411281 Free PMC article.
202. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment. D'Onofrio N, Sardù C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, Panarese I, Petrella L, Fanelli M, Modugno P, Massetti M, Marfella LV, Sasso FC, Rizzo MR, Barbieri M, Furbatto F,

- Minicucci F, Mauro C, Federici M, Balestrieri ML, Paolisso G, Marfella R. *Mol Metab.* 2021 Dec;54:101337. doi: 10.1016/j.molmet.2021.101337. Epub 2021 Sep 7. PMID: 34500107 Free PMC article.
203. Metabolic characteristics in patients with COVID-19 and no-COVID-19 interstitial pneumonia with mild-to-moderate symptoms and similar radiological severity. Rizza S, Nucera A, Chiocchi M, Bellia A, Mereu D, Ferrazza G, Ballanti M, Davato F, Di Cola G, Buonomo CO, Coppeta L, Vanni G, Gervasi R, Cardellini M, Lauro D, Federici M. *Nutr Metab Cardiovasc Dis.* 2021 Oct 28;31(11):3227-3235. doi: 10.1016/j.numecd.2021.08.035. Epub 2021 Aug 18. PMID: 34629249 Free PMC article.
 204. Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life. Rizza S, Piciocchi G, Mavilio M, Longo S, Montagna M, Tatonetti R, Nucera A, Federici M. *Biomed Pharmacother.* 2021 Dec;144:112341. doi: 10.1016/j.biopha.2021.112341. Epub 2021 Oct 19. PMID: 34678725
 205. Impact of environmental pollution and weather changes on the incidence of ST-elevation myocardial infarction. Biondi-Zoccai G, Frati G, Gaspardone A, Mariano E, Di Giosa AD, Bolignano A, Dei Giudici A, Calcagno S, Scappaticci M, Sciarretta S, Valenti V, Casati R, Visconti G, Penco M, Giannico MB, Peruzzi M, Cavarretta E, Budassi S, Cosma J, Federici M, Roeber L, Romeo F, Versaci F. *Eur J Prev Cardiol.* 2021 Oct 25;28(13):1501-1507. doi: 10.1177/2047487320928450. Epub 2020 Jun 2. PMID: 34695216
 206. Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon. Mayneris-Perxachs J, Moreno-Navarrete JM, Ballanti M, Monteleone G, Alessandro Paoluzi O, Mingrone G, Lefebvre P, Staels B, Federici M, Puig J, Garre J, Ramos R, Fernández-Real JM. *Comput Struct Biotechnol J.* 2021;19:6080-6089. doi: 10.1016/j.csbj.2021.11.007. Epub 2021 Nov 8. PMID: 34777716 Free PMC article.
 207. Non-targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function. Puetz A, Artati A, Adamski J, Schuett K, Romeo F, Stoeck R, Marx N, Federici M, Lehrke M, Kappel BA. *ESC Heart Fail.* 2022 Feb;9(1):564-573. doi: 10.1002/ehf2.13713. Epub 2021 Nov 22. PMID: 34811951 Free PMC article.
 208. High Sensitivity C-Reactive Protein Increases the Risk of Carotid Plaque Instability in Male Dyslipidemic Patients. Scimeca M, Montanaro M, Cardellini M, Bonfiglio R, Anemona L, Urbano N, Bonanno E, Menghini R, Casagrande V, Martelli E, Servadei F, Giacobbi E, Ippoliti A, Bei R, Manzari V, Federici M, Schillaci O, Mauriello A. *Diagnostics (Basel).* 2021 Nov 15;11(11):2117. doi: 10.3390/diagnostics11112117. PMID: 34829465 Free PMC article.
 209. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO); Members of the guidelines panel; Coordinator; AISF Members; SID Members; SIO Members; Metodologists. *Nutr Metab Cardiovasc Dis.* 2022 Jan;32(1):1-16. doi: 10.1016/j.numecd.2021.04.028. Epub 2021 Dec 16. PMID: 34924246
 210. Enterocyte superoxide dismutase 2 deletion drives obesity. Garcia-Irigoyen O, Bovenga F, Piglionica M, Piccinin E, Cariello M, Arconzo M, Peres C, Corsetto PA, Rizzo AM, Ballanti M, Menghini R, Mingrone G, Lefebvre P, Staels B, Shirasawa T, Sabbà C, Villani G, Federici M, Moschetta A. *iScience.* 2021 Dec 27;25(1):103707. doi: 10.1016/j.isci.2021.103707. eCollection 2022 Jan 21. PMID: 35036884 Free PMC article.
 211. ITCH E3 ubiquitin ligase downregulation compromises hepatic degradation of branched-chain amino acids. Menghini R, Hoyles L, Cardellini M, Casagrande V, Marino A, Gentileschi P, Davato F, Mavilio M, Arisi I, Mauriello A, Montanaro M, Scimeca M, Barton RH, Rappa F, Cappello F, Vinciguerra M, Moreno-Navarrete JM, Ricart W, Porzio O, Fernández-Real JM, Burcelin R, Dumas ME, Federici M. *Mol Metab.* 2022 May;59:101454. doi: 10.1016/j.molmet.2022.101454. Epub 2022 Feb 9. PMID: 35150905 Free PMC article.
 212. Autoantibodies against the glial glutamate transporter GLT1/EAAT2 in Type 1 diabetes mellitus-Clues to novel immunological and non-immunological therapies. Perego C, Di Cairano ES, Galli A, Moretti S, Bazzigaluppi E, Centonze VF, Gastaldelli A, Assi E, Fiorina P, Federici M,

- Porzio O, Bertuzzi F, Davalli AM, Folli F. *Pharmacol Res.* 2022 Mar;177:106130. doi: 10.1016/j.phrs.2022.106130. Epub 2022 Feb 10. PMID: 35151858
213. COVID-19-Associated Endothelial Dysfunction and Microvascular Injury: From Pathophysiology to Clinical Manifestations. Canale MP, Menghini R, Martelli E, Federici M. *Card Electrophysiol Clin.* 2022 Mar;14(1):21-28. doi: 10.1016/j.ccep.2021.10.003. Epub 2021 Oct 30. PMID: 35221082 Free PMC article. Review.
 214. Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? Bonanni M, Rehak L, Massaro G, Benedetto D, Matteucci A, Russo G, Esperto F, Federici M, Mauriello A, Sangiorgi GM. *Biomedicines.* 2022 May 8;10(5):1091. doi: 10.3390/biomedicines10051091. PMID: 35625828 Free PMC article. Review.
 215. Editorial: Hyperglycemia and Coronary Artery Diseases: Physio-Pathological Findings and Therapeutic Implications. Marfella R, Federici M, Paolisso G. *Front Pharmacol.* 2022 May 19;13:901815. doi: 10.3389/fphar.2022.901815. eCollection 2022. PMID: 35662710 Free PMC article. No abstract available.
 216. Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation. Morelli C, Rofei M, Riondino S, Fraboni D, Torino F, Orlandi A, Tesaro M, Del Vecchio Blanco G, Federici M, Arkenau HT, Formica V, Roselli M. *Cancers (Basel).* 2022 May 24;14(11):2594. doi: 10.3390/cancers14112594. PMID: 35681576 Free PMC article.
 217. How the First Year of the COVID-19 Pandemic Impacted Patients' Hospital Admission and Care in the Vascular Surgery Divisions of the Southern Regions of the Italian Peninsula. Martelli E, Sotgiu G, Saderi L, Federici M, Sangiorgi G, Zamboni M, Martelli AR, Accarino G, Bianco G, Bonanno F, Bracale UM, Cappello E, Cioffi G, Colacchio G, Crinisio A, De Vivo S, Dionisi CP, Flora L, Impedovo G, Intrieri F, Iorio L, Maritati G, Modugno P, Monaco M, Natalicchio G, Palazzo V, Petrosino F, Pompeo F, Pulli R, Razzano D, Ruggieri MR, Ruotolo C, Sangiuolo P, Vigliotti G, Volpe P, Biello A, Boggia P, Boschetti M, Centritto EM, Condò F, Cucciolillo L, D'Amodio AS, De Laurentis M, Desantis C, Di Lella D, Di Nardo G, Disabato A, Ficarelli I, Gasparre A, Giordano AN, Luongo A, Massara M, Molinari V, Padricelli A, Panagrosso M, Petrone A, Pisanello S, Prunella R, Tedesco M, Settembrini AM. *J Pers Med.* 2022 Jul 19;12(7):1170. doi: 10.3390/jpm12071170. PMID: 35887667 Free PMC article.
 218. Impact of light therapy on rotating night shift workers: the EuRhythDia study. Rizza S, Luzi A, Mavilio M, Ballanti M, Massimi A, Porzio O, Magrini A, Hannemann J, Menghini R, Cridland J, Staels B, Grant PJ, Boger RH, Marx N, Federici M. *Acta Diabetol.* 2022 Dec;59(12):1589-1596. doi: 10.1007/s00592-022-01956-2. Epub 2022 Aug 31. PMID: 36044097 Free PMC article. Clinical Trial.
 219. DPP9 as a Potential Novel Mediator in Gastrointestinal Virus Infection. Del Castillo-Izquierdo Á, Moreno-Navarrete JM, Latorre J, Arnoriaga-Rodríguez M, Ballanti M, Monteleone G, Alessandro Paoluzi O, Mingrone G, Puig J, Ramos R, Garre-Olmo J, Jové M, Pamplona R, Portero-Otín M, Sol J, Lefebvre P, Staels B, Federici M, Fernández-Real JM, Mayneris-Perxachs J. *Antioxidants (Basel).* 2022 Nov 3;11(11):2177. doi: 10.3390/antiox11112177. PMID: 36358551 Free PMC article.
 220. Liver lipopolysaccharide binding protein prevents hepatic inflammation in physiological and pathological non-obesogenic conditions. Milbank E, Díaz-Trelles R, Dragano N, Latorre J, Mukthavaram R, Mayneris-Perxachs J, Ortega F, Federici M, Burcelin R, Karmali PP, Tachikawa K, Chivukula P, López M, Fernández-Real JM, Moreno-Navarrete JM. *Pharmacol Res.* 2023 Jan;187:106562. doi: 10.1016/j.phrs.2022.106562. Epub 2022 Nov 21. PMID: 36410673
 221. Antibiotic-induced gut microbiota depletion exacerbates host hypercholesterolemia. Kappel BA, De Angelis L, Puetz A, Ballanti M, Menghini R, Marx N, Federici M. *Pharmacol Res.* 2023 Jan;187:106570. doi: 10.1016/j.phrs.2022.106570. Epub 2022 Nov 21. PMID: 36423788
 222. Human liver microbiota modeling strategy at the early onset of fibrosis. Champion C, Neagoe RM, Efferenberger M, Sala DT, Servant F, Christensen JE, Arnoriaga-Rodríguez M, Amar J, Lelouvier B, Loubieres P, Azalbert V, Minty M, Thomas C, Blasco-Baque V, Gamboa F, Tilg H, Cardellini M, Federici M, Fernández-Real JM, Loubes JM, Burcelin R. *BMC Microbiol.* 2023 Jan 30;23(1):34. doi: 10.1186/s12866-023-02774-4. PMID: 36717776 Free PMC article.

223. Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial. Chiarito M, Sanz-Sanchez J, Piccolo R, Condello F, Luccardo G, Maurina M, Avvedimento M, Regazzoli D, Pagnotta P, Garcia-Garcia HM, Mehran R, Federici M, Condorelli G, Diez Gil JL, Reimers B, Ferrante G, Stefanini G. *Cardiovasc Diabetol*. 2023 Feb 6;22(1):28. doi: 10.1186/s12933-023-01744-4. PMID: 36747244 Free PMC article. Clinical Trial.
224. The emerging role of sodium-glucose cotransporter 2 inhibitors in heart failure. Gitto M, Villaschi A, Federici M, Condorelli G, Stefanini GG. *Curr Pharm Des*. 2023 Feb 17. doi: 10.2174/1381612829666230217143324. Online ahead of print. PMID: 36799420
225. Dynapenia, Muscle Quality, and Hepatic Steatosis in Patients with Obesity and Sarcopenic Obesity. Frigerio F, De Marinis M, Camardella F, Cantisani V, Pinto A, Bernardi M, Lubrano C, Gnassi L, Federici M, Donini LM, Poggiogalle E. *Biomedicines*. 2023 Feb 6;11(2):472. doi: 10.3390/biomedicines11020472. PMID: 36831008 Free PMC article.
226. Sex-Related Differences and Factors Associated with Peri-Procedural and 1 Year Mortality in Chronic Limb-Threatening Ischemia Patients from the CLIMATE Italian Registry. Martelli E, Zamboni M, Sotgiu G, Saderi L, Federici M, Sangiorgi GM, Puci MV, Martelli AR, Messina T, Frigatti P, Borrelli MP, Ruotolo C, Ficarella I, Rubino P, Pezzo F, Carbonari L, Angelini A, Galeazzi E, Di Pinto LC, Fiore FM, Palmieri A, Ventoruzzo G, Mazzitelli G, Ragni F, Bozzani A, Forliti E, Castagno C, Volpe P, Massara M, Moniaci D, Pagliasso E, Peretti T, Ferrari M, Troisi N, Modugno P, Maiorano M, Bracale UM, Panagrosso M, Monaco M, Giordano G, Natalicchio G, Biello A, Celoria GM, Amico A, Di Bartolo M, Martelli M, Munaó R, Razzano D, Colacchio G, Bussetti F, Lanza G, Cardini A, Di Benedetto B, De Laurentis M, Taurino M, Sirignano P, Cappiello P, Esposito A, Trimarchi S, Romagnoli S, Padricelli A, Giudice G, Crinisio A, Di Nardo G, Battaglia G, Tringale R, De Vivo S, Compagna R, Tolva VS, D'Alessio I, Curci R, Giovannetti S, D'Arrigo G, Basile G, Frigerio D, Veraldi GF, Mezzetto L, Ippoliti A, Oddi FM, Settembrini AM. *J Pers Med*. 2023 Feb 11;13(2):316. doi: 10.3390/jpm13020316. PMID: 36836550 Free PMC article.
227. Impact of Insulin Degludec/Liraglutide Fixed Combination on the Gut Microbiomes of Elderly Patients With Type 2 Diabetes: Results From A Subanalysis of A Small Non-Randomised Single Arm Study. Rizza S, Pietrucci D, Longo S, Menghini R, Teofani A, Piciucchi G, Montagna M, Federici M. *Aging Dis*. 2023 Apr 1;14(2):319-324. doi: 10.14336/AD.2023.0118. eCollection 2023 Apr 1. PMID: 37008061 Free PMC article.
228. Vasovagal syncope: An overview of pathophysiological mechanisms. Longo S, Legramante JM, Rizza S, Federici M. *Eur J Intern Med*. 2023 Jun;112:6-14. doi: 10.1016/j.ejim.2023.03.025. Epub 2023 Apr 6. PMID: 37030995 Review.
229. Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes. Longo S, Rizza S, Federici M. *Acta Diabetol*. 2023 Aug;60(8):1007-1017. doi: 10.1007/s00592-023-02088-x. Epub 2023 Apr 14. PMID: 37058160 Free PMC article. Review.
230. Pancreatic beta-cell specific BAG3 knockout results in chronic hyperinsulinemia inducing insulin resistance. Damiani V, Lamolinara A, Cicalini I, Cufaro MC, Del Pizzo F, Di Marco F, Del Boccio P, Dufrusine B, Hahne M, Lattanzio R, Pieragostino D, Iezzi M, Federici M, Turco MC, Maiorana A, Dionisi-Vici C, De Laurenzi V. *Mol Metab*. 2023 Aug;74:101752. doi: 10.1016/j.molmet.2023.101752. Epub 2023 Jun 10. PMID: 37308077 Free PMC article.
231. GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform? Menghini R, Casagrande V, Rizza S, Federici M. *Acta Diabetol*. 2023 Nov;60(11):1441-1448. doi: 10.1007/s00592-023-02124-w. Epub 2023 Jul 4. PMID: 37401947 Free PMC article. Review.
232. Immunomodulation Therapies for Atherosclerosis: The Past, the Present, and the Future. Lecis D, Massaro G, Benedetto D, Di Luozzo M, Russo G, Mauriello A, Federici M, Sangiorgi GM. *Int J Mol Sci*. 2023 Jul 1;24(13):10979. doi: 10.3390/ijms241310979. PMID: 37446157 Free PMC article. Review.
233. The visceral adipose tissue bacterial microbiota provides a signature of obesity based on inferred metagenomic functions. Sun J, Germain A, Kaglan G, Servant F, Lelouvier B, Federici M, Fernandez-Real JM, Sala DT, Neagoe RM, Bouloumié A, Burcelin R. *Int J Obes (Lond)*. 2023 Oct;47(10):1008-1022. doi: 10.1038/s41366-023-01341-1. Epub 2023 Jul 24. PMID: 37488221
234. Focus on the Most Common Paucisymptomatic Vasculopathic Population, from Diagnosis to Secondary Prevention of Complications. Martelli E, Enea I, Zamboni M, Federici M,

- Bracale UM, Sangiorgi G, Martelli AR, Messina T, Settembrini AM. *Diagnostics* (Basel). 2023 Jul 13;13(14):2356. doi: 10.3390/diagnostics13142356. PMID: 37510100 Free PMC article. Review.
235. Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target? Belli M, Barone L, Longo S, Prandi FR, Lecis D, Mollace R, Margonato D, Muscoli S, Sergi D, Federici M, Barillà F. *Int J Mol Sci.* 2023 Jul 26;24(15):11971. doi: 10.3390/ijms241511971. PMID: 37569352 Free PMC article. Review.
 236. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N; ESC Scientific Document Group. *Eur Heart J.* 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192. PMID: 37622663 No abstract available.
 237. Bergamot Polyphenolic Extract Combined with Albedo and Pulp Fibres Counteracts Changes in Gut Microbiota Associated with High-Fat Diet: Implications for Lipoprotein Size Re-Arrangement. Mollace R, Macrì R, Nicita M, Musolino V, Gliozzi M, Carresi C, Bava I, Maiuolo J, Tavernese A, Cardamone A, Tucci L, Trunfio G, Janda E, Palma E, Muscoli C, Barillà F, Federici M, Scarano F, Mollace V. *Int J Mol Sci.* 2023 Aug 19;24(16):12967. doi: 10.3390/ijms241612967. PMID: 37629146 Free PMC article.
 238. Modulation of the nitric oxide/cGMP pathway in cardiac contraction and relaxation: Potential role in heart failure treatment. Mollace R, Scarano F, Bava I, Carresi C, Maiuolo J, Tavernese A, Gliozzi M, Musolino V, Muscoli S, Palma E, Muscoli C, Salvemini D, Federici M, Macrì R, Mollace V. *Pharmacol Res.* 2023 Oct;196:106931. doi: 10.1016/j.phrs.2023.106931. Epub 2023 Sep 16. PMID: 37722519 Review.
 239. Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE. Ferrigno S, Conigliaro P, Rizza S, Longo S, Nesi C, Carlucci F, Bergamini A, Mancino R, Nucci C, Federici M, Chimenti MS, Cesareo M. *Lupus Sci Med.* 2023 Oct;10(2):e000977. doi: 10.1136/lupus-2023-000977. PMID: 37852671 Free PMC article.
 240. Macrophage polarization and metabolism in atherosclerosis. Hou P, Fang J, Liu Z, Shi Y, Agostini M, Bernassola F, Bove P, Candi E, Rovella V, Sica G, Sun Q, Wang Y, Scimeca M, Federici M, Mauriello A, Melino G. *Cell Death Dis.* 2023 Oct 20;14(10):691. doi: 10.1038/s41419-023-06206-z. PMID: 37863894 Free PMC article. Review.
 241. Hannemann J, Laing A, Middleton B, Schwedhelm E, Marx N, Federici M, Kastner M, Skene DJ, Böger R. Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study. *Pharmacol Res.* 2024 Jan;199:107011. doi: 10.1016/j.phrs.2023.107011. Epub 2023 Nov 27. PMID: 38029806.
 242. European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. *Lancet.* 2024 Jan 6;403(10421):55-66. doi:10.1016/S0140-6736(23)01842-1. Epub 2023 Dec 12. PMID: 38101429.
 243. Quesada-Vázquez S, Castells-Nobau A, Latorre J, Oliveras-Cañellas N, Puig-Parnau I, Tejera N, Tobajas Y, Baudin J, Hildebrand F, Beraza N, Burcelin R, Martinez-Gili L, Chilloux J, Dumas ME, Federici M, Hoyles L, Caimari A, Del Bas JM, Escoté X, Fernández-Real JM, Mayneris-Perxachs J. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity. *Cell Rep Med.* 2023 Dec 19;4(12):101341. doi: 10.1016/j.xcrm.2023.101341. PMID: 38118419; PMCID: PMC10772641.
 245. Lecis D, Prandi FR, Barone L, Belli M, Sergi D, Longo S, Muscoli S, Romeo F, Federici M, Lerakis S, Barillà F. Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born? *Biomolecules.* 2023 Nov 23;13(12):1695. doi: 10.3390/biom13121695. PMID: 38136567; PMCID: PMC10741698.

246. Schütt K, Federici M, Verket M, Marx N, Müller-Wieland D. The '10 commandments' for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. *Eur Heart J*. 2024 Apr 14;45(15):1298-1300. doi: 10.1093/eurheartj/ehad881. PMID: 38195096.
247. Villaschi A, Ferrante G, Cannata F, Pini D, Pagnesi M, Corrada E, Reimers B, Mehran R, Federici M, Savarese G, Metra M, Condorelli G, Stefanini GG, Chiarito M. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. *Clin Res Cardiol*. 2024 Jun;113(6):898-909. doi: 10.1007/s00392-023-02362-6. Epub 2024 Jan 22. PMID: 38252145.
248. Casagrande V, Menini S, Internò C, Pugliese G, Federici M, Menghini R. TIMP3 overexpression in myeloid lineage alleviates pancreatic damage and confers resistance to the development of type 1 diabetes in the MLDS-induced model. *Front Endocrinol (Lausanne)*. 2024 Jan 19;14:1297847. doi: 10.3389/fendo.2023.1297847. PMID: 38313841; PMCID: PMC10835381.
249. Caminiti R, Carresi C, Mollace R, Macrì R, Scarano F, Oppedisano F, Maiuolo J, Serra M, Ruga S, Nucera S, Tavernese A, Gliozzi M, Musolino V, Palma E, Muscoli C, Rubattu S, Volterrani M, Federici M, Volpe M, Mollace V. The potential effect of natural antioxidants on endothelial dysfunction associated with arterial hypertension. *Front Cardiovasc Med*. 2024 Feb 2;11:1345218. doi: 10.3389/fcvm.2024.1345218. PMID: 38370153; PMCID: PMC10869541.
250. Longo S, Del Chierico F, Scanu M, Toto F, Legramante JM, Rizza S, Putignani L, Federici M. An Investigation of Metabolic Risk Factors and Gut Microbiota in Unexplained Syncope. *Biomedicines*. 2024 Jan 24;12(2):264. doi: 10.3390/biomedicines12020264. PMID: 38397866; PMCID: PMC10886590.
251. Longo S, Cassandra F, Cardolini I, Montagna M, Nucera A, Federici M. Double mutation in genes associated to FH and diabetes. *Acta Diabetol*. 2024 May;61(5):671-674. doi: 10.1007/s00592-024-02235-y. Epub 2024 Feb 29. PMID: 38424212.
252. Ballanti M, Antonetti L, Mavilio M, Casagrande V, Moscatelli A, Pietrucci D, Teofani A, Internò C, Cardellini M, Paoluzi O, Monteleone G, Lefebvre P, Staels B, Mingrone G, Menghini R, Federici M. Decreased circulating IPA levels identify subjects with metabolic comorbidities: A multi-omics study. *Pharmacol Res*. 2024 May 9;204:107207. doi: 10.1016/j.phrs.2024.107207. Epub ahead of print. PMID: 38734193.
253. Castells-Nobau A, Moreno-Navarrete JM, de la Vega-Correa L, Puig I, Federici M, Sun J, Burcelin R, Guzylack-Piriou L, Gourdy P, Cazals L, Arnoriaga-Rodríguez M, Frühbeck G, Seoane LM, López-Miranda J, Tinahones FJ, Dieguez C, Dumas ME, Pérez-Brocal V, Moya A, Perakakis N, Mingrone G, Bornstein S, Rodriguez Hermosa JI, Castro E, Fernández-Real JM, Mayneris-Perxachs J. Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism. *Gut*. 2025 Jan 17;74(2):229-245. doi: 10.1136/gutjnl-2024-332602.
254. European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC). Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study. *Lancet Diabetes Endocrinol*. 2024 Nov;12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3.
255. Marx N, Rydén L, Federici M, Marx-Schütt K, Verket M, Müller-Wieland D, Gerstein HC, Chan J, Cosentino F, Holman RR, Mellbin L, Ray KK, Standl E, Verma S, Wood D, Tuomilehto J, De Caterina R. Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction. *Eur Heart J*. 2024 Dec 23;45(48):5117-5126. doi: 10.1093/eurheartj/ehae533

256. Mollace R, Longo S, Nardin M, Tavernese A, Musolino V, Cardamone A, Federici M. Role of MASLD in CVD: A review of emerging treatment options. *Diabetes Res Clin Pract.* 2024 Nov;217:111891. doi: 10.1016/j.diabres.2024.111891.
257. Longo S, Cicalini I, Pieragostino D, De Laurenzi V, Legramante JM, Menghini R, Rizza S, Federici M. A Metabolomic Approach to Unexplained Syncope. *Biomedicines.* 2024 Nov 19;12(11):2641. doi: 10.3390/biomedicines12112641.
258. Antonetti L, Berrilli F, Di Cristanziano V, Farowski F, Daeumer M, Eberhardt KA, Santoro M, Federici M, D'Alfonso R. Investigation of gut microbiota composition in humans carrying blastocystis subtypes 1 and 2 and Entamoeba hartmanni. *Gut Pathog.* 2024 Nov 29;16(1):72. doi: 10.1186/s13099-024-00661-5.
259. Minty M, Germain A, Sun J, Kaglan G, Servant F, Lelouvier B, Misselis E, Neagoe RM, Rossella M, Cardellini M, Burcelin R, Federici M, Fernandez-Real JM, Blasco-Baque V. Identifying the location-dependent adipose tissue bacterial DNA signatures in obese patients that predict body weight loss. *Gut Microbes.* 2025 Dec;17(1):2439105. doi: 10.1080/19490976.2024.2439105.
260. Castera L, Alazawi W, Bugianesi E, Caussy C, Federici M, Romero-Gómez M, Schattenberg JM, Basuroy R, Prasad P, Estulin D, Lazarus JV. A European Survey to Identify Challenges in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease. *Liver Int.* 2025 Feb;45(2):e16224. doi: 10.1111/liv.16224
261. Tavernese A, Cammalleri V, Mollace R, Antonelli G, Piscione M, Cocco N, Carpenito M, Dominici C, Federici M, Ussia GP. The Role of Advanced Cardiac Imaging in Monitoring Cardiovascular Complications in Patients with Extracardiac Tumors: A Descriptive Review. *J Cardiovasc Dev Dis.* 2024 Dec 29;12(1):9. doi: 10.3390/jcdd12010009.
262. Marx N, Schütt K, Müller-Wieland D, Di Angelantonio E, Herrington WG, Ajjan RA, Kautzky-Willer A, Rocca B, Sattar N, Fauchier L, Lettino M, Federici M, Members of the Task Force for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes in low-resource settings. *Eur Heart J Qual Care Clin Outcomes.* 2025 Mar 28;qcae105.
263. Picchi E, Di Giuliano F, Pucci N, Sallustio F, Minosse S, Mascolo AP, Marrama F, Ferrazzoli V, Da Ros V, Diomedi M, Federici M, Garaci F. CT Perfusion Imaging in Patients with Acute Ischemic Stroke: The Role of Premorbid Statin Treatment. *Tomography.* 2025 May 6;11(5):54. doi: 10.3390/tomography11050054. PMID: 40423256
264. Rizza S, Coppeta L, Ferrazza G, Nucera A, Postorino M, Quatrana A, Ferrari C, Menghini R, Longo S, Magrini A, Federici M. Nuclear Factor Erythroid 2-Related Factor 2 and SARS-CoV-2 Infection Risk in COVID-19-Vaccinated Hospital Nurses. *Vaccines (Basel).* 2025 Jul 9;13(7):739.
265. Hou G, Zhang G, Zheng Y, Zhang S, Federici M, Meng P, Wang F, Zhang B, Jannini EA, Yuan J. Uncovering novel therapeutic targets for premature ejaculation from gut microbiota: A prospective high-throughput sequencing study. *Andrology.* 2025 Jul 22. doi: 10.1111/andr.70099.
266. Fatica M, Ferrigno S, Çela E, D'Antonio A, Conigliaro P, Cardellini M, Longo S, Federici M, Chimenti MS. Metabolic challenges of glucose and lipid dysregulation in psoriatic arthritis: a narrative review from pathogenesis to clinical practice. *Acta Diabetol.* 2025 Aug 14. doi: 10.1007/s00592-025-02565-5.
267. Lena AM, Smirnov A, Mancini M, Montanaro M, Ciccocanti F, Foti V, Nardacci R, Fimia GM, Mavilio M, Federici M, Mauriello A, Piacentini M, Melino G, Candi E. Deletion of p63 exon 13 in mice reveals C-terminal isoform-specific functions in epithelial development. *Proc Natl Acad Sci U S A.* 2025 Jul 22;122(29):e2503866122.

268. Lucia S, Fornaro S, Federici M, Rumiati RI. The impact of type 2 diabetes on aging: multidimensional approaches to preserve cognitive health. *Acta Diabetol.* 2025 Sep 2. doi: 10.1007/s00592-025-02583-3.
269. Corrao S, Federici M. Unmasking heterogeneity in type 2 diabetes: the clinical relevance of phenotyping in the era of precision medicine. *Acta Diabetol.* 2025 Aug;62(8):1167-1172.
270. Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. *J Am Coll Cardiol.* 2025 Aug 27:S0735-1097(25)07492-3.
271. Servadei F, Scimeca M, Palumbo V, Oddi FM, Bonfiglio R, Giacobbi E, Menghini R, Casagrande V, Cardellini M, Martelli E, Candi E, Melino G, Federici M, Ippoliti A, Mauriello A. Aging and Sex Modify the Risk of Carotid Plaque Thrombosis Related to Dyslipidemic Profile. *Stroke.* 2025 Oct;56(10):2879-2887.
272. Casagrande V, Panarello L, Lepri A, Quatrana A, Internò C, Antonetti L, Bonanno E, Cicalini I, Pieragostino D, Gorgels A, De Laurenzi V, Goettsch C, Cardellini M, Federici M, Menghini R. Effect of 3-hydroxyisobutyrate in vivo administration on cardiometabolic disease in ApoE^{-/-} mouse model. *Pharmacol Res.* 2025 Oct;220:107943. doi: 10.1016/j.phrs.2025.107943.

Ai sensi della legge 679/2016 del Regolamento del Parlamento Europeo del 27 aprile 2016, esprimo il mio consenso al trattamento e all'utilizzo dei dati forniti nel presente CV.

Roma, 11/12/2025

F.to Massimo Federici

Riproduzione in formato privacy del documento originale depositato agli atti.